{"gene":"TJP2","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1994,"finding":"ZO-2 (TJP2) was found to coimmunoprecipitate with ZO-1 from MDCK cell extracts, identifying it as a tight junction-associated peripheral membrane protein that interacts with ZO-1. ZO-2 contains a region homologous to ZO-1 including guanylate kinase-like and PDZ domains (MAGUK family). ZO-2 localizes exclusively at cytoplasmic surfaces of tight junctions in epithelia (liver, intestine, kidney, testis, arterial endothelium) but is absent from the fascia adherens in cardiac myocytes, unlike ZO-1.","method":"Coimmunoprecipitation from MDCK cells, polyclonal antibody against unique ZO-2 region, immunohistochemistry of frozen tissue sections, double-label immunofluorescence","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP plus immunolocalization across multiple tissues, foundational characterization paper replicated by subsequent work","pmids":["8132716"],"is_preprint":false},{"year":1996,"finding":"ZO-2 contains three PDZ domains, an SH3 domain, and a guanylate kinase-like domain. An alternatively spliced 36-amino acid domain exists in the C-terminal proline-rich region. The PDZ and protein-binding domains are highly conserved relative to ZO-1, while the C-terminal regions are divergent (25% identity), suggesting distinct functions.","method":"Full-length cDNA sequencing and sequence analysis of multiple ZO-2 cDNAs","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Strong — comprehensive sequence characterization of a single protein, replicated by later structural studies, but primary method is cDNA analysis","pmids":["8824195"],"is_preprint":false},{"year":1999,"finding":"ZO-2 binds directly to the COOH-terminal YV sequence of claudin-1 through -8 via its PDZ1 domain in vitro. In cells lacking ZO-1, ZO-2 is recruited to claudin-based networks through both PDZ2 (ZO-2)/PDZ2 (ZO-1) interactions and PDZ1 (ZO-2)/claudin-COOH interactions.","method":"In vitro binding assays with purified recombinant PDZ domains, transfection of claudins into L fibroblasts, immunofluorescence colocalization","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with recombinant proteins plus cell-based validation, independently replicated across multiple labs","pmids":["10601346"],"is_preprint":false},{"year":1999,"finding":"ZO-2 directly binds F-actin in vitro (cosedimentation assay) but does not act as an F-actin cross-linking protein and does not bind actin filament ends. ZO-2 also directly binds ZO-1 and occludin. Immunoprecipitation showed ZO-1 and ZO-2 exist primarily as independent ZO-1·ZO-2 complexes rather than a trimeric ZO-1·ZO-2·ZO-3 complex in situ.","method":"Actin cosedimentation assays with purified recombinant proteins, low-speed sedimentation analyses, immunoprecipitation, immunofluorescence colocalization in cytochalasin D-treated MDCK cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro binding reconstitution plus immunoprecipitation in two orthogonal methods, single lab","pmids":["10575001"],"is_preprint":false},{"year":1999,"finding":"The NH2-terminal fragment of cingulin (residues 1-378) interacts in vitro with ZO-2 in pull-down assays from epithelial lysates. ZO-2 immunoprecipitates contain cingulin, confirming an in vivo interaction.","method":"Pull-down assays from epithelial and insect cell lysates, co-immunoprecipitation","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and pull-down, single lab, two orthogonal methods","pmids":["10613913"],"is_preprint":false},{"year":2000,"finding":"Protein 4.1R isoforms (135 and 150 kDa) specifically interact with ZO-2 via residues encoded by exons 19-21 of 4.1R and residues 1054-1118 of ZO-2, as determined by yeast two-hybrid, in vitro binding, and co-immunoprecipitation. 4.1R co-localizes with ZO-2 and occludin at MDCK tight junctions and co-precipitates with ZO-2, ZO-1, occludin, actin, and alpha-spectrin, suggesting 4.1R links the tight junction to the actin cytoskeleton through ZO-2.","method":"Yeast two-hybrid system, in vitro binding studies, immunocolocalization, immunoprecipitation, Western blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus reciprocal co-IP plus in vitro binding, single lab, multiple orthogonal methods with domain mapping","pmids":["10874042"],"is_preprint":false},{"year":2001,"finding":"Adenovirus type 9 E4-ORF1 oncoprotein selectively targets ZO-2 (acting as a candidate tumor suppressor). Complex formation is mediated by the C-terminal PDZ-binding motif of Ad9 E4-ORF1 and the first PDZ domain of ZO-2. This interaction results in aberrant cytoplasmic sequestration of ZO-2. Overexpression of wild-type ZO-2 (but not mutant ZO-2 lacking PDZ2 and PDZ3) interfered with Ad9 E4-ORF1-induced focus formation.","method":"Co-immunoprecipitation, immunofluorescence colocalization, focus formation assay, ZO-2 overexpression/mutant rescue experiments","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus functional rescue with domain-mapping mutants, single lab","pmids":["11598001"],"is_preprint":false},{"year":2002,"finding":"ZO-2 localizes to the nucleus in sparse epithelial cultures, accumulating in clusters that partially colocalize with splicing factor SC35. Nuclear staining diminishes as cultures reach confluence. Nuclear-to-cytoplasm shuttling is sensitive to leptomycin B (nuclear export inhibitor) and is mediated by the actin cytoskeleton. ZO-2 shuttling to the nucleus uses a pre-existing pool, not newly synthesized protein.","method":"Immunofluorescence in MDCK cells at varying confluence, leptomycin B treatment, mechanical injury assay, cell-cell contact disruption, protein synthesis inhibition","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiments with multiple pharmacological perturbations, single lab","pmids":["11855865"],"is_preprint":false},{"year":2002,"finding":"Nuclear ZO-2 directly interacts with the DNA-binding protein scaffold attachment factor-B (SAF-B) via its PDZ1 domain, as shown by yeast two-hybrid assays and in vivo co-immunoprecipitation. EGFP-ZO-2 and DsRed-SAF-B fusion proteins partially co-localize in nuclei of transfected epithelial cells. No association of SAF-B with ZO-1 was found.","method":"Yeast two-hybrid assay, co-immunoprecipitation from epithelial cells, confocal microscopy of fluorescently-tagged fusion proteins","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus co-IP in cells, single lab, two orthogonal methods","pmids":["12403786"],"is_preprint":false},{"year":2003,"finding":"A mutation in the first PDZ domain of TJP2/ZO-2 (associated with familial hypercholanemia in Amish individuals) reduces PDZ1 domain stability and ligand binding in vitro. Hepatic tight junctions show a morphological change in individuals with this mutation.","method":"In vitro domain stability and ligand binding assays with recombinant PDZ1 domain mutant, electron microscopy of liver biopsies","journal":"Nature genetics","confidence":"Medium","confidence_rationale":"Tier 1-2 / Weak — in vitro biochemical assay on isolated domain plus structural microscopy, single study","pmids":["12704386"],"is_preprint":false},{"year":2003,"finding":"Tyrosine phosphorylation of the C-terminal tail of occludin (by c-Src in vitro) markedly reduces its binding to ZO-2 (as well as ZO-1 and ZO-3), but does not affect occludin binding to F-actin.","method":"In vitro phosphorylation of GST-fused C-occludin by c-Src, in vitro binding assays with ZO-2","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstituted kinase assay with mutagenesis-equivalent phosphomimetic approach, single lab, single method","pmids":["12604349"],"is_preprint":false},{"year":2004,"finding":"ZO-2 associates with transcription factors Jun, Fos, and C/EBP both at the nucleus and at tight junction regions of epithelial cells. This association was confirmed by pull-down assays, gel shift analysis, and co-immunoprecipitation. ZO-2 down-regulates AP-1-controlled gene transcription in a dose-dependent manner; both the amino and carboxyl domains of ZO-2 are capable of inhibiting gene transcription.","method":"Pull-down assays with ZO-2 GST fusion proteins, gel shift (EMSA), co-immunoprecipitation, immunolocalization, CAT reporter gene assays","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pull-down plus co-IP plus functional reporter assay, single lab, multiple orthogonal methods","pmids":["14720506"],"is_preprint":false},{"year":2004,"finding":"ZO-2 is present in the nuclear matrix and co-immunoprecipitates with lamin B1 and actin from nuclei of sparse cultures. ZO-2 contains multiple nuclear localization signals (NLS) at its amino region; deletion of these NLS diminishes nuclear import and impairs the ability to regulate AP-1-controlled transcriptional activity. ZO-2 contains a functional nuclear export signal (NES2) at the GK region that is leptomycin B-sensitive.","method":"Nuclear fractionation, co-immunoprecipitation from nuclear fractions, NLS deletion mutants transfection, nuclear export assay with ovalbumin-conjugated NES peptides, leptomycin B sensitivity, reporter gene assay","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — nuclear fractionation with co-IP plus functional NLS/NES mapping with multiple mutants, single lab","pmids":["15194440"],"is_preprint":false},{"year":2004,"finding":"ARVCF interacts with ZO-2 via a C-terminal PDZ-binding motif on ARVCF and the PDZ domains of ZO-2. Nuclear localization of ARVCF is dependent on this PDZ-binding motif and can be mediated specifically by the PDZ domains of ZO-2 (but not equivalently by ZO-1). Disruption of cell-cell adhesion releases ARVCF from the plasma membrane, with an increased fraction localizing to the nucleus.","method":"Co-immunoprecipitation, yeast two-hybrid, fluorescence microscopy, domain-mapping using PDZ-binding motif mutants, calcium-switch assay","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus functional rescue with domain mutants, single lab","pmids":["15456900"],"is_preprint":false},{"year":2005,"finding":"hScrib (mammalian Scribble homolog) directly interacts with ZO-2 via two PDZ domains of hScrib and the C-terminal PDZ-binding motif of ZO-2. Both proteins colocalize at cell-cell junctions. A point mutation in the LRR of hScrib delocalizes it from the plasma membrane and abrogates the interaction with ZO-2.","method":"GST pull-down, co-immunoprecipitation, immunofluorescence colocalization, LRR point-mutant analysis","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pull-down plus co-IP plus domain mapping mutants, single lab","pmids":["15975580"],"is_preprint":false},{"year":2006,"finding":"ZO-1 and ZO-2 independently determine where claudins are polymerized during tight junction strand formation. In cells lacking both ZO-1 and ZO-2 (ZO-1 knockout/ZO-2 knockdown), tight junctions are completely absent despite normal cell polarity. Re-expression of either ZO-1 or ZO-2 alone restores claudin polymerization and tight junction formation. A truncated ZO-1 containing only PDZ1-3 was insufficient; forced membrane recruitment and dimerization of this truncated form restored claudin polymerization.","method":"Homologous recombination, RNAi knockdown, exogenous rescue by transfection, immunofluorescence, transepithelial resistance measurement","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO/KD with domain-mapping rescue experiments, multiple orthogonal methods, high-impact independent study","pmids":["16923393"],"is_preprint":false},{"year":2006,"finding":"ZO-2 contains four nuclear export signals (NES-0, NES-1 in PDZ2; NES-2, NES-3 in GK region). NES-0 and NES-3 are functional and leptomycin B-sensitive. NES-1, previously thought non-functional, becomes active upon acquisition of negative charge at Ser369. Efficient nuclear exit of ZO-2 amino and middle segments requires paired NES; mutation of any single NES in full-length ZO-2 induces nuclear accumulation.","method":"Nuclear export assay using ovalbumin-conjugated NES peptides microinjected into nuclei of MDCK cells, leptomycin B sensitivity, transfection of full-length ZO-2 NES mutants","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional nuclear export assay with multiple NES mutants, single lab","pmids":["16920099"],"is_preprint":false},{"year":2007,"finding":"ZO-2 silencing in MDCK cells increases paracellular permeability to dextran (gate function impairment), disrupts fence function (non-polarized E-cadherin distribution), decreases occludin and E-cadherin protein levels, delays arrival of ZO-1, occludin and E-cadherin to the plasma membrane during calcium switch, and produces atypical monolayer architecture with widened intercellular spaces, multistratification, and altered actin patterns.","method":"siRNA knockdown in MDCK cells, transepithelial electrical resistance measurement, dextran flux assay, calcium switch assay, immunofluorescence, Western blot","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean siRNA KD with multiple functional phenotypic readouts, single lab","pmids":["17374535"],"is_preprint":false},{"year":2007,"finding":"ZO-2 down-regulates cyclin D1 transcription in a dose-dependent manner via an E box in the cyclin D1 promoter, reducing cell proliferation. ZO-2 does not directly bind DNA but recruits c-Myc (confirmed by EMSA, ChIP, and co-immunoprecipitation) and HDAC1 to the E box. HDAC activity is required for ZO-2-mediated repression.","method":"CAT reporter gene assays with cyclin D1 promoter deletions, EMSA, chromatin immunoprecipitation (ChIP), co-immunoprecipitation, HDAC inhibitor treatment, wound-healing proliferation assay","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (reporter, EMSA, ChIP, co-IP) in single lab establishing mechanism of cyclin D1 repression","pmids":["17881732"],"is_preprint":false},{"year":2008,"finding":"ZO-2 knockout mice die shortly after implantation due to arrest in early gastrulation, demonstrating a non-redundant and critical role of ZO-2 in mammalian development. ZO-2−/− embryos show decreased proliferation at E6.5, increased apoptosis at E7.5, altered apical junctional complex architecture, and increased paracellular permeability. ZO-3 knockout mice have no obvious phenotype, indicating ZO-3 is dispensable.","method":"Gene targeting (ZO-2 and ZO-3 knockout mice), embryo histology and immunohistochemistry, paracellular tracer permeability assay, TUNEL/BrdU assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean in vivo genetic KO with multiple phenotypic readouts including barrier function measurement","pmids":["18172007"],"is_preprint":false},{"year":2008,"finding":"ZO-1 and ZO-2 are both required for integration of myosin-2 into the epithelial zonula adherens (ZA). In ZO-1/ZO-2 double-depleted cells, a fragmented adherens junction (prezonula-AJ) positive for E-cadherin and actin but negative for myosin-2 forms. Re-expression of full-length ZO-1 or ZO-2 (or ZO-1 lacking PDZ1/2 but not PDZ1/2/3) restores myosin-2 integration. ZO-1/ZO-2 regulate RhoA-dependent spatiotemporal Rho activation for ZA establishment.","method":"Conditional ZO-1 KO/ZO-2 KD cell lines, rescue by transfection of truncation mutants, immunofluorescence, FRET analysis of Rho activation, dominant-active RhoA/ROCK transfection","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic depletion plus domain-mapping rescue plus FRET-based signaling readout, multiple orthogonal methods","pmids":["18596233"],"is_preprint":false},{"year":2008,"finding":"In mouse preimplantation embryos, ZO-2 is expressed from both maternal and embryonic genomes; maternal ZO-2 protein associates with nuclei in zygotes and early cleavage stages. ZO-2 siRNA knockdown in zygotes delayed blastocoel cavity formation but did not block cell proliferation. ZO-2-deficient embryos compensatorily increased ZO-1 (but not occludin) assembly at tight junctions.","method":"siRNA microinjection into mouse zygotes/2-cell embryos, immunofluorescence, quantitative junctional analysis, blastocoel measurement","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA KD in embryos with functional blastocoel formation readout, single lab","pmids":["18817772"],"is_preprint":false},{"year":2010,"finding":"ZO-2 uses its first PDZ domain to form a complex with YAP2. Endogenous ZO-2 and YAP2 co-localize in the nucleus. ZO-2 facilitates the nuclear localization and pro-apoptotic function of YAP2 in a PDZ-domain-dependent manner.","method":"Co-immunoprecipitation, co-localization by immunofluorescence, PDZ-domain deletion mutant analysis, nuclear localization and apoptosis assays","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with domain-mapping mutants and functional nuclear localization/apoptosis readout, single lab","pmids":["20868367"],"is_preprint":false},{"year":2010,"finding":"Genomic duplication of TJP2 in a family with progressive nonsyndromic hearing loss DFNA51 leads to overexpression of TJP2 transcript and protein. TJP2 overexpression in affected family members leads to decreased phosphorylation of GSK-3β and altered expression of apoptosis-regulating genes, suggesting a mechanism for progressive hair cell death.","method":"SNP array genomic analysis, RT-PCR, Western blot, immunohistochemistry of inner ear tissue, phospho-GSK-3β Western blot, expression profiling of apoptosis genes","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genomic, molecular, and signaling characterization in patient cells, single study","pmids":["20602916"],"is_preprint":false},{"year":2013,"finding":"JAM-A directly associates with ZO-2 (and indirectly with afadin), and this complex together with PDZ-GEF1 activates the small GTPase Rap2c. siRNA-mediated downregulation of JAM-A, ZO-2, afadin, or PDZ-GEF1 results in enhanced epithelial permeability, indicating ZO-2 is a functional component of the JAM-A/afadin/PDZ-GEF1/Rap2c signaling module that regulates barrier function.","method":"Co-immunoprecipitation, siRNA knockdown, transepithelial resistance and permeability assays, GTPase activity assays","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus siRNA KD with functional barrier readout, single lab","pmids":["23885123"],"is_preprint":false},{"year":2013,"finding":"SNX27 interacts with ZO-2 via the PDZ domain of SNX27 and the C-terminal PDZ-binding motif of ZO-2. Upon tight junction disruption by calcium chelation, ZO-2 transiently localizes to SNX27-positive early endosomes. SNX27 depletion decreases ZO-2 (but not ZO-1) mobility at cell-cell contacts (FRAP) and increases junctional permeability to large solutes.","method":"Proteomic interaction screen, co-immunoprecipitation, confocal immunofluorescence, FRAP, siRNA knockdown, permeability assays","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomic screen plus co-IP plus FRAP plus functional permeability readout, single lab, multiple orthogonal methods","pmids":["23826934"],"is_preprint":false},{"year":2014,"finding":"Protein-truncating mutations in TJP2 cause failure of protein localization to tight junctions and disruption of tight-junction structure, resulting in severe progressive cholestatic liver disease. This contrasts with embryonic-lethal knockout in mice, highlighting species and organ-specific redundancy differences.","method":"Next-generation sequencing, immunohistochemistry and electron microscopy of liver biopsies, protein localization studies in patient tissue","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct demonstration of protein mislocalization caused by truncating mutations in patient tissue, replicated across multiple patients","pmids":["24614073"],"is_preprint":false},{"year":2016,"finding":"ZO-2 silencing in MDCK renal epithelial cells induces cell hypertrophy via two mechanisms: (1) prolonging G1 phase due to elevated cyclin D1, and (2) augmenting protein synthesis via nuclear accumulation and increased transcriptional activity of YAP, which decreases PTEN expression, elevating PIP3 and activating Akt/mTOR/S6K1 signaling. In uninephrectomized rats, compensatory renal hypertrophy is accompanied by decreased ZO-2 and nuclear YAP expression.","method":"siRNA knockdown in MDCK cells, cell cycle analysis, protein synthesis measurement, YAP localization and activity assays, PTEN/Akt/mTOR/S6K1 Western blot, uninephrectomy rat model, immunofluorescence","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — siRNA KD with multiple orthogonal functional readouts (cell cycle, protein synthesis, signaling pathway) plus in vivo rat model, single lab","pmids":["27009203"],"is_preprint":false},{"year":2016,"finding":"ZO-2 is SUMOylated by the SUMO machinery; it associates with E2 SUMO-conjugating enzyme Ubc9 and SUMO-deconjugating proteases SENP1 and SENP3. SUMOylation site K730 in human ZO-2 (GuK domain) was identified; mutation K730R results in prolonged nuclear localization. A construct mimicking constitutive SUMOylation (SUMO1ΔGG-ZO-2) localizes preferentially to the cytoplasm. ZO-2 directly binds GSK3β, and cytosolic SUMO1ΔGG-ZO-2 modulates GSK3β kinase activity. ZO-2 also forms a complex with β-catenin, and wild-type ZO-2 inhibits β-catenin/TCF-4 transcriptional activity.","method":"Co-immunoprecipitation, Ubc9 fusion-directed SUMOylation, SENP1 inhibition assays, site-directed mutagenesis (K730R), nuclear recruitment assay, reporter gene assay, GSK3β kinase activity assay","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (co-IP, SUMOylation assay, mutagenesis, kinase assay, reporter), single lab","pmids":["27604867"],"is_preprint":false},{"year":2018,"finding":"The organophosphate pesticide methamidophos (MET) forms covalent bonds with ZO-2 at serine, tyrosine, and lysine residues. MET induces phosphorylation of ZO-2 and reduces the interaction between ZO-2 and occludin. MET targets ubiquitination sites on ZO-2 (including a lysine residue), and mutation of a MET-target lysine residue in ZO-2 interferes with TJ sealing in epithelial cells.","method":"Mass spectrometry (covalent modification identification), co-immunoprecipitation, Western blot (phosphorylation), transfection of ZO-2 mutants into epithelial cells, transepithelial resistance measurement","journal":"Toxicology and applied pharmacology","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — mass spectrometry identification of covalent modification sites plus functional mutagenesis rescue, single lab","pmids":["30291936"],"is_preprint":false},{"year":2019,"finding":"CaSR activation by Gd3+ triggers ZO-2 concentration at tight junctions via PKC activation, which phosphorylates and activates WNK4, which in turn phosphorylates ZO-2, inducing its TJ localization. In low calcium, ZO-2 is protected from degradation by association with 14-3-3 proteins (ζ and σ). The ZO-2/14-3-3 complexes move to cell borders upon calcium restoration and then dissociate. The unique region 2 of ZO-2 and S261 (within an NLS) are critical for the interaction with 14-3-3 proteins and for efficient nuclear importation.","method":"Co-immunoprecipitation, pharmacological inhibition (CaSR agonist Gd3+, PKC/WNK4 inhibitors), site-directed mutagenesis (S261 and unique region 2 mutants), immunofluorescence, Western blot","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus pharmacological pathway dissection plus site-directed mutagenesis, single lab","pmids":["31318316"],"is_preprint":false},{"year":2021,"finding":"ZO-2 tight junction protein modulates nuclear accumulation of TEAD transcription factor. ZO-2 knockdown reduces nuclear TEAD; ZO-2 lacking NLS does not facilitate TEAD nuclear entry. Inhibition of nPKCδ in parental cells triggers cytoplasmic ZO-2/TEAD interaction and facilitates ZO-2/TEAD complex nuclear importation. nPKCε activates a ZO-2 nuclear export signal to enhance TEAD nuclear exit. ZO-2/TEAD interaction was confirmed by proximity ligation, co-immunoprecipitation, and pull-down assays.","method":"Proximity ligation assay, co-immunoprecipitation, pull-down assay, nPKCδ/ε inhibitor treatment, ZO-2 NLS mutant transfection, immunofluorescence of TEAD localization","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal interaction methods plus pharmacological pathway mapping plus functional nuclear localization readout, single lab","pmids":["34010016"],"is_preprint":false},{"year":2021,"finding":"Liver-specific deletion of Tjp2 in mice results in lower claudin-1 protein levels, dilated canaliculi, lower microvilli density, aberrant radixin and BSEP (Abcb11) distribution, and mild progressive cholestasis with reduced Abcb11/Bsep and Cyp2b10 expression. Cholic acid diet causes severe cholestasis and liver necrosis in Tjp2-deficient mice. Combined hepatocyte and cholangiocyte deletion was necessary for severe CA-induced injury.","method":"Conditional liver-specific Cre-lox knockout (hepatocyte-specific and cholangiocyte-specific), electron microscopy, immunostaining, biochemical analysis, FITC-dextran permeability assay, cholic acid diet challenge","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional cell-type-specific KO with multiple functional and structural readouts, in vivo model","pmids":["33465371"],"is_preprint":false},{"year":2021,"finding":"ZO-2 associates with LATS1 (Hippo kinase), functioning as a scaffold for the Hippo pathway. ZO-2 silencing is accompanied by diminished LATS activity and nuclear concentration of YAP in renal epithelial cells, in uninephrectomized rat kidneys, and in liver steatosis in obese Zucker rats.","method":"Co-immunoprecipitation (ZO-2/LATS1), immunofluorescence of YAP localization, LATS kinase activity assay, siRNA knockdown, in vivo uninephrectomy rat model, obese Zucker rat model","journal":"Tissue barriers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus in vivo models plus siRNA KD with signaling readout, single lab","pmids":["34689705"],"is_preprint":false},{"year":2022,"finding":"Liver-specific Tjp2 deletion in mice leads to DDC-diet-induced hepatocyte-to-cholangiocyte transdifferentiation, which is Yap/Wwtr1(Taz)-dependent and cell-autonomous to hepatocytes (not cholangiocytes). Tjp2 inactivation is sufficient to upregulate Yap and Taz protein expression in hepatocytes, but efficient transdifferentiation additionally requires the DDC-diet insult. Notch2 is not required.","method":"Conditional Tjp2 KO (hepatocyte-specific and cholangiocyte-specific), DDC diet challenge, Yap/Taz genetic inactivation experiments, immunostaining, lineage tracing","journal":"NPJ Regenerative medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific conditional KO with genetic epistasis (Yap/Taz), single lab","pmids":["36151109"],"is_preprint":false},{"year":2022,"finding":"Residues K759 and K992 in human ZO-2 are acceptors for K48-linked polyubiquitination (targeting for proteasomal degradation); mutation to arginine increases ZO-2 half-life from ~20 to ~37 h. Residue K730 (the SUMOylation site) mutation increases ubiquitination and decreases ZO-2 half-life to ~6.7 h. Mutations at K759, K992, or K730 all decrease the TJ sealing peak (transepithelial resistance).","method":"Co-immunoprecipitation with ubiquitin antibodies, TUBE (tandem ubiquitin-binding entity) assay for K48-polyubiquitin, site-directed mutagenesis of K730, K759, K992, half-life measurement by cycloheximide chase, transepithelial resistance measurement","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — TUBE-based K48-ubiquitin identification plus mutagenesis plus functional TER readout, single lab","pmids":["36291162"],"is_preprint":false},{"year":2023,"finding":"ZNF582 binds to TJP2/ZO-2 protein and upregulates TJP2 protein expression. Increased TJP2 combines with ERK2 to promote ERK2 protein expression and suppresses phosphorylation of ERK2, thereby inhibiting ccRCC growth and metastasis.","method":"TMT quantitative proteomics, co-immunoprecipitation, Western blot, cell phenotype and orthotopic tumor experiments","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus proteomics plus functional oncology assays, single lab","pmids":["36966163"],"is_preprint":false},{"year":2023,"finding":"p190A RhoGAP interacts with ZO-2 in a manner dependent on RasGAP. Both RasGAP and ZO-2 are required for p190A to activate LATS kinases, elicit mesenchymal-to-epithelial transition, promote contact inhibition, suppress tumorigenesis, and transcriptionally modulate target genes. Low ARHGAP35 expression combined with high TJP2 expression predicts shorter survival.","method":"Co-immunoprecipitation, siRNA knockdown of ZO-2/RasGAP, LATS kinase activity assay, cell proliferation/contact inhibition assays, in vivo tumorigenesis models, reporter gene assay","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus siRNA KD with epistatic functional readouts, single lab","pmids":["37995182"],"is_preprint":false},{"year":2024,"finding":"ZO-2 is required for contact-mediated inhibition of proliferation. ZO-2 acts as a scaffold that promotes LATS1-YAP interaction: ZO-2 binds LATS1 via its SH3 domain and YAP via its PDZ domains, thereby facilitating LATS1-mediated phosphorylation of YAP, leading to YAP cytoplasmic retention and inactivation. ZO-2 also promotes LATS1 stability.","method":"Co-immunoprecipitation with domain-specific ZO-2 mutants (SH3 and PDZ domain mutations), YAP phosphorylation assay, cell proliferation/contact inhibition assays, LATS1 stability measurement","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with domain-mapping mutants plus kinase activity and stability readout, single lab","pmids":["39462647"],"is_preprint":false},{"year":2024,"finding":"ZO-2 loss reduces apical membrane rigidity (measured by AFM), inhibits γ-actin and JAM-A recruitment to the cell border, and facilitates p114RhoGEF and afadin accumulation at junctions, leading to increased TJ mechanical tension (measured by FRET ZO-1 tension probe) and increased tricellular TJ tension. ZO-2 KD cells show impaired responses to substrate stiffness and topography, and increased nuclear YAP and Snail.","method":"Atomic force microscopy, FRET tension probes (ZO-1 and E-cadherin), immunofluorescence, siRNA knockdown, AFM membrane rigidity measurement, nanostructured substrate assays","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — AFM plus FRET-based tension measurement plus immunofluorescence, single lab, multiple methods","pmids":["38473701"],"is_preprint":false},{"year":2025,"finding":"ZO-2 colocalizes with CEP164 at the distal appendage of the mother centriole and is present at mitotic spindle poles, the basal body of primary cilia, and the tail of spermatozoa. ZO-2 depletion inhibits astral and mitotic spindle microtubule (EB1-expressing) development, reduces KIF14 and TPX2 at spindle poles, increases NuMA accumulation, and decreases p-Aurora levels, leading to reduced spindle length, microtubule instability, and abnormal chromosome congression. ZO-2 co-immunoprecipitates with KIF14, NuMA, and p-Aurora; NuMA and Aurora-A bind different segments of ZO-2. ZO-2 depletion also reduces primary cilium development and blocks Sonic Hedgehog signaling.","method":"Co-immunoprecipitation with ZO-2 segments, immunofluorescence colocalization, siRNA knockdown, spindle length and morphology analysis, EB1 live imaging, SHH reporter assay","journal":"Cell and tissue research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus siRNA KD with multiple cellular phenotype readouts (spindle, cilia, signaling), single lab","pmids":["40728639"],"is_preprint":false},{"year":2025,"finding":"c-Abl kinase directly binds to and phosphorylates the C-terminus of ZO-2, and also stimulates JAK1, which subsequently phosphorylates the N-terminus of ZO-2. c-Abl regulates cellular morphology and migration through ZO-2 phosphorylation (demonstrated by RNAi knockdown/rescue strategy). c-Abl activity is associated with decreased traction forces on the substrate.","method":"In vitro kinase assay (c-Abl phosphorylation of ZO-2 C-terminus), immunoprecipitation of c-Abl/ZO-2 complex, RNAi knockdown/rescue, traction force microscopy, cell migration assay","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase assay plus RNAi rescue plus functional migration readout, single lab","pmids":["41259016"],"is_preprint":false},{"year":2026,"finding":"ZO-2 directly binds to NTCP (the HBV receptor sodium taurocholate cotransporting polypeptide), and this interaction is required for NTCP cell surface localization. ZO-2 knockdown or knockout decreases NTCP at the cell surface, reducing HBV attachment and infection. HBV surface protein preS1 binding causes dissociation of the NTCP/ZO-2 complex and formation of NTCP-preS1-actin complexes that internalize into cells. Actin polymerization is required for preS1 internalization and HBV infection (latrunculin A blocks this). ZO-1 and ZO-3 knockdown had no effect on HBV infection.","method":"Immunopurification/LC-MS/MS (interaction discovery), co-immunoprecipitation, ZO-2 KD/KO, NTCP cell surface flow cytometry, HBV infection assay, preS1 binding assay, latrunculin A treatment","journal":"mBio","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomic interaction discovery plus co-IP plus KD/KO plus functional viral infection readout, single lab","pmids":["41870046"],"is_preprint":false}],"current_model":"TJP2/ZO-2 is a MAGUK scaffold protein that physically links claudins (via PDZ1), occludin, JAM-A, and NTCP to the actin cytoskeleton at epithelial tight junctions, independently drives claudin polymerization and tight junction strand formation, undergoes regulated nuclear–cytoplasmic shuttling (controlled by NLS/NES sequences, SUMOylation at K730, ubiquitination at K759/K992, and 14-3-3 binding) where it represses AP-1/cyclin D1/YAP-TEAD transcription, scaffolds LATS1 to phosphorylate and inactivate YAP (Hippo pathway), and is also found at centrioles/spindle poles where it promotes microtubule stability; loss-of-function mutations in humans cause progressive cholestatic liver disease due to disrupted hepatocellular tight junction structure and impaired bile transporter localization."},"narrative":{"mechanistic_narrative":"TJP2 (ZO-2) is a MAGUK-family scaffold protein that organizes epithelial tight junctions and couples them to transcriptional and cytoskeletal control of cell growth [PMID:8132716, PMID:16923393]. As a tight junction-associated peripheral membrane protein bearing three PDZ domains, an SH3 domain, and a guanylate kinase-like domain, it directly binds claudins via PDZ1, ZO-1, occludin, and F-actin, physically linking transmembrane junction components to the cortical actin cytoskeleton [PMID:8824195, PMID:10601346, PMID:10575001]. ZO-1 and ZO-2 independently determine where claudins polymerize into tight junction strands, and cells lacking both fail to form tight junctions altogether; either protein alone restores strand assembly [PMID:16923393], and ZO-2 loss impairs both gate and fence functions and delays junctional protein recruitment [PMID:17374535]. ZO-2 is essential in development, as its knockout causes peri-implantation embryonic lethality from gastrulation arrest [PMID:18172007]. Beyond the junction, ZO-2 undergoes regulated nuclear-cytoplasmic shuttling governed by amino-terminal NLS sequences, multiple leptomycin B-sensitive nuclear export signals, SUMOylation at K730, K48-polyubiquitination at K759/K992, and 14-3-3 binding, which together tune its abundance and localization [PMID:15194440, PMID:16920099, PMID:27604867, PMID:36291162, PMID:31318316]. In the nucleus it represses transcription, down-regulating AP-1 target genes and repressing cyclin D1 by recruiting c-Myc and HDAC1 to an E-box, thereby restraining proliferation [PMID:14720506, PMID:17881732]. ZO-2 acts as a Hippo-pathway scaffold, binding LATS1 through its SH3 domain and YAP through its PDZ domains to promote LATS1-mediated phosphorylation and cytoplasmic retention of YAP, enforcing contact inhibition of proliferation; its loss drives nuclear YAP/TEAD activity, PTEN suppression, Akt/mTOR signaling and cellular hypertrophy [PMID:27009203, PMID:34689705, PMID:39462647, PMID:34010016]. ZO-2 also localizes to centrioles and spindle poles, where it supports mitotic spindle microtubule stability and primary cilium formation [PMID:40728639]. In humans, protein-truncating TJP2 mutations cause failure of tight-junction localization and progressive cholestatic liver disease, recapitulated by liver-specific deletion in mice that mislocalizes bile transporters and disrupts canalicular architecture [PMID:24614073, PMID:33465371].","teleology":[{"year":1994,"claim":"Established TJP2/ZO-2 as a distinct tight junction-associated MAGUK protein, answering whether it was a bona fide junctional component separate from ZO-1.","evidence":"Co-immunoprecipitation with ZO-1 from MDCK cells and immunolocalization across epithelial tissues","pmids":["8132716"],"confidence":"High","gaps":["Direct binding partners at the junction not yet mapped to specific domains","Functional role beyond ZO-1 association unknown"]},{"year":1996,"claim":"Defined the modular domain architecture (three PDZ, SH3, GK domains) and divergent C-terminus, framing how ZO-2 might engage distinct ligands from ZO-1.","evidence":"Full-length cDNA sequencing and comparative sequence analysis","pmids":["8824195"],"confidence":"Medium","gaps":["Functional assignment of individual domains not tested","Significance of the alternatively spliced region unresolved"]},{"year":1999,"claim":"Resolved how ZO-2 bridges transmembrane junction proteins to the cytoskeleton, identifying claudin (PDZ1), ZO-1, occludin, F-actin, and cingulin as direct partners.","evidence":"In vitro binding with recombinant PDZ domains, actin cosedimentation, co-immunoprecipitation in MDCK and epithelial lysates","pmids":["10601346","10575001","10613913"],"confidence":"High","gaps":["Stoichiometry and dynamics of the claudin/ZO complex in living strands not defined","Whether ZO-2 actin binding is regulated unaddressed"]},{"year":2000,"claim":"Extended the cytoskeletal linkage by mapping a 4.1R/spectrin connection through a defined ZO-2 segment, reinforcing a tight-junction-to-actin scaffold.","evidence":"Yeast two-hybrid, in vitro binding, co-immunoprecipitation, immunocolocalization in MDCK cells","pmids":["10874042"],"confidence":"High","gaps":["Functional consequence of disrupting the 4.1R/ZO-2 link not tested","Tissue-specificity of the interaction unknown"]},{"year":2002,"claim":"Revealed a non-junctional nuclear pool of ZO-2 that shuttles in a density- and export-dependent manner and binds nuclear partners, opening a transcriptional role.","evidence":"Confluence-dependent immunofluorescence, leptomycin B sensitivity, yeast two-hybrid and co-IP with SAF-B","pmids":["11855865","12403786"],"confidence":"Medium","gaps":["Transcriptional output of nuclear ZO-2 not yet demonstrated","Import/export signals not yet mapped"]},{"year":2004,"claim":"Defined ZO-2 as a transcriptional repressor and mapped its NLS/NES shuttling determinants, linking junctional localization to gene control of AP-1 targets.","evidence":"Pull-down, EMSA, co-IP with Jun/Fos/C-EBP, reporter assays, nuclear fractionation and NLS/NES mutant analysis","pmids":["14720506","15194440"],"confidence":"Medium","gaps":["Direct DNA binding excluded but full repressor complex undefined","Physiological triggers of nuclear entry incomplete"]},{"year":2006,"claim":"Demonstrated that ZO-1 and ZO-2 are independently sufficient to drive claudin polymerization and tight-junction strand formation, establishing a core organizational function.","evidence":"ZO-1 KO/ZO-2 knockdown cells with domain-mapped rescue, immunofluorescence, TER measurement","pmids":["16923393","16920099"],"confidence":"High","gaps":["Mechanism by which scaffolds template claudin polymerization not structurally defined","Relative in vivo contributions of ZO-1 vs ZO-2 unresolved"]},{"year":2007,"claim":"Showed ZO-2 controls both gate and fence functions and the kinetics of junctional protein assembly, and represses cyclin D1 to restrain proliferation, linking junction integrity to growth control.","evidence":"siRNA knockdown with TER/dextran flux/calcium switch assays; reporter, EMSA, ChIP and co-IP for cyclin D1 repression via c-Myc/HDAC1","pmids":["17374535","17881732"],"confidence":"High","gaps":["How junctional vs nuclear pools coordinate growth signaling not dissected","HDAC1 recruitment mechanism partial"]},{"year":2008,"claim":"Established the in vivo essentiality of ZO-2 (embryonic lethality) and its role in adherens junction maturation via RhoA-dependent myosin-2 integration.","evidence":"ZO-2 and ZO-3 knockout mice with histology/permeability assays; ZO-1/ZO-2 double-depletion with FRET Rho activation and rescue","pmids":["18172007","18596233","18817772"],"confidence":"High","gaps":["Molecular basis of gastrulation arrest unresolved","Link between Rho regulation and junction defect mechanistically incomplete"]},{"year":2010,"claim":"Connected ZO-2 to YAP, showing PDZ1-dependent complex formation that modulates YAP nuclear localization and function, foreshadowing a Hippo-pathway role.","evidence":"Co-IP, colocalization, PDZ-deletion mutants, nuclear localization and apoptosis assays","pmids":["20868367"],"confidence":"Medium","gaps":["Context-dependence of pro- vs anti-growth YAP outcomes unclear","Upstream Hippo kinase link not yet established"]},{"year":2014,"claim":"Established TJP2 truncating mutations as a cause of human progressive cholestatic liver disease through failed junctional localization, defining a Mendelian disease link.","evidence":"Next-generation sequencing and patient liver biopsy immunohistochemistry/electron microscopy","pmids":["24614073"],"confidence":"High","gaps":["Mechanism connecting junction disruption to bile transport not yet defined in vivo","Species difference vs embryonic-lethal mouse unexplained"]},{"year":2016,"claim":"Linked ZO-2 loss to cellular hypertrophy through dual cyclin D1 (G1) and YAP-PTEN-Akt/mTOR mechanisms, and mapped SUMOylation (K730) as a shuttling switch that also tunes GSK3-beta and beta-catenin signaling.","evidence":"siRNA knockdown with cell-cycle/protein-synthesis/signaling readouts and uninephrectomy rat model; Ubc9/SENP SUMOylation assays and K730R mutagenesis","pmids":["27009203","27604867"],"confidence":"High","gaps":["Direct LATS link to YAP regulation not yet shown here","How SUMO and other PTMs are integrated in vivo unclear"]},{"year":2019,"claim":"Defined PTM- and 14-3-3-controlled regulation of ZO-2 stability and localization downstream of calcium/CaSR-PKC-WNK4 signaling, explaining how junction assembly is dynamically tuned.","evidence":"Co-IP, CaSR/PKC/WNK4 pharmacology, S261 and unique-region-2 mutagenesis, immunofluorescence","pmids":["31318316"],"confidence":"Medium","gaps":["Physiological calcium contexts driving this in vivo not addressed","Interplay with SUMO/ubiquitin codes not integrated"]},{"year":2021,"claim":"Solidified ZO-2 as a Hippo scaffold and TEAD-localization regulator, and established cell-type-specific liver phenotypes including YAP/TAZ-dependent hepatocyte transdifferentiation.","evidence":"Co-IP with LATS1, PLA/pull-down for TEAD, nPKC pharmacology, conditional liver Tjp2 KO with cholic acid/DDC challenge and Yap/Taz genetic epistasis","pmids":["34689705","34010016","33465371","36151109"],"confidence":"High","gaps":["Quantitative contribution of junctional vs nuclear ZO-2 to Hippo output unresolved","How transporter mislocalization arises mechanistically incomplete"]},{"year":2022,"claim":"Mapped K48-polyubiquitination acceptor sites (K759/K992) controlling ZO-2 half-life and showed PTM crosstalk with the K730 SUMO site, tying degradation control to tight-junction sealing.","evidence":"TUBE assay, ubiquitin co-IP, K730/K759/K992 mutagenesis, cycloheximide chase, TER measurement","pmids":["36291162"],"confidence":"Medium","gaps":["E3 ligase responsible for ZO-2 ubiquitination not identified","In vivo relevance of half-life control untested"]},{"year":2023,"claim":"Extended ZO-2's growth-suppressive scaffolding into LATS-dependent contact inhibition and tumor suppression via p190A RhoGAP, and into ERK2 modulation downstream of ZNF582.","evidence":"Co-IP, siRNA knockdown, LATS kinase assays, in vivo tumorigenesis and proteomics/ccRCC models","pmids":["37995182","36966163"],"confidence":"Medium","gaps":["Direct vs indirect nature of some interactions not fully resolved","Tissue-specificity of tumor-suppressive vs other roles unclear"]},{"year":2024,"claim":"Provided the domain-level mechanism by which ZO-2 scaffolds LATS1-YAP (SH3 binds LATS1, PDZ binds YAP) and stabilizes LATS1, and revealed ZO-2 control of junctional mechanics and tension.","evidence":"Co-IP with SH3/PDZ mutants, YAP phosphorylation and LATS1 stability assays; AFM and FRET tension probes with siRNA knockdown","pmids":["39462647","38473701"],"confidence":"Medium","gaps":["Structural basis of the LATS1-ZO-2-YAP assembly not solved","How mechanical state feeds back to Hippo output incomplete"]},{"year":2025,"claim":"Uncovered non-junctional roles of ZO-2 at centrioles/spindle poles in microtubule stability and ciliogenesis, plus phosphoregulation by c-Abl/JAK1 and a requirement for NTCP surface display and HBV infection.","evidence":"Co-IP with ZO-2 segments, EB1 live imaging and spindle analysis; in vitro c-Abl kinase assay with RNAi rescue and traction force microscopy; LC-MS/MS, KD/KO and HBV infection assays","pmids":["40728639","41259016","41870046"],"confidence":"Medium","gaps":["Mechanism coupling ZO-2 to spindle pole factors not structurally defined","Whether NTCP/HBV role generalizes beyond hepatocytes untested"]},{"year":null,"claim":"How the integrated PTM code (SUMO/ubiquitin/phosphorylation/14-3-3) and the choice between junctional, nuclear, and centrosomal ZO-2 pools are coordinated in vivo to dictate barrier function versus growth control remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of full-length ZO-2 in any scaffolding complex","E3 ligase and full PTM regulatory network unidentified","Causal link between junctional disruption and bile transporter mislocalization mechanistically incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,3,5,38]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[3,5]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[11,18]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[33,38]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,2,17]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[7,12,22]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[11,18]},{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[40]},{"term_id":"GO:0005929","term_label":"cilium","supporting_discovery_ids":[40]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[25]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[24,27,33,38]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[11,18,31]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0,2,15,17]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[18,27,40]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[19,34]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[26,32,42]}],"complexes":["tight junction","JAM-A/afadin/PDZ-GEF1/Rap2c module","LATS1-ZO-2-YAP Hippo scaffold"],"partners":["TJP1","CLDN1","OCLN","F11R","LATS1","YAP1","SLC10A1","ACTN"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UDY2","full_name":"Tight junction protein 2","aliases":["Tight junction protein ZO-2","Zona occludens protein 2","Zonula occludens protein 2"],"length_aa":1190,"mass_kda":134.0,"function":"Plays a role in tight junctions and adherens junctions (By similarity). Acts as a positive regulator of RANKL-induced osteoclast differentiation, potentially via mediating downstream transcriptional activity (By similarity)","subcellular_location":"Cell junction, adherens junction; Cell membrane; Cell junction, tight junction; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9UDY2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TJP2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000119139","cell_line_id":"CID000737","localizations":[{"compartment":"cell_contact","grade":3},{"compartment":"cytoplasmic","grade":1}],"interactors":[{"gene":"TJP1","stoichiometry":10.0},{"gene":"BCKDK","stoichiometry":4.0},{"gene":"CALD1","stoichiometry":0.2},{"gene":"CAPZB","stoichiometry":0.2},{"gene":"MAGI1","stoichiometry":0.2},{"gene":"PGAM5","stoichiometry":0.2},{"gene":"BIN3","stoichiometry":0.2},{"gene":"KIF14","stoichiometry":0.2},{"gene":"GTF2H5","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000737","total_profiled":1310},"omim":[{"mim_id":"619658","title":"CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 7, WITH OR WITHOUT HEARING LOSS; PFIC7","url":"https://www.omim.org/entry/619658"},{"mim_id":"619232","title":"HYPERCHOLANEMIA, FAMILIAL 3; FHCA3","url":"https://www.omim.org/entry/619232"},{"mim_id":"617677","title":"ZO2-ASSOCIATED SPECKLE PROTEIN","url":"https://www.omim.org/entry/617677"},{"mim_id":"617431","title":"UBIQUITIN-SPECIFIC PEPTIDASE 53; USP53","url":"https://www.omim.org/entry/617431"},{"mim_id":"615878","title":"CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC, 4; PFIC4","url":"https://www.omim.org/entry/615878"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Plasma membrane","reliability":"Enhanced"},{"location":"Cell Junctions","reliability":"Enhanced"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TJP2"},"hgnc":{"alias_symbol":["ZO-2","X104","ZO2"],"prev_symbol":["DFNA51"]},"alphafold":{"accession":"Q9UDY2","domains":[{"cath_id":"2.30.42.10","chopping":"26-124","consensus_level":"high","plddt":86.1002,"start":26,"end":124},{"cath_id":"2.30.42.10","chopping":"307-384","consensus_level":"high","plddt":86.9264,"start":307,"end":384},{"cath_id":"2.30.42.10","chopping":"501-673","consensus_level":"medium","plddt":90.8371,"start":501,"end":673},{"cath_id":"3.40.50.300","chopping":"727-890_897-919","consensus_level":"high","plddt":84.7832,"start":727,"end":919}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UDY2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UDY2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UDY2-F1-predicted_aligned_error_v6.png","plddt_mean":63.03},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TJP2","jax_strain_url":"https://www.jax.org/strain/search?query=TJP2"},"sequence":{"accession":"Q9UDY2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UDY2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UDY2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UDY2"}},"corpus_meta":[{"pmid":"10601346","id":"PMC_10601346","title":"Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins.","date":"1999","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10601346","citation_count":923,"is_preprint":false},{"pmid":"16923393","id":"PMC_16923393","title":"ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16923393","citation_count":661,"is_preprint":false},{"pmid":"8132716","id":"PMC_8132716","title":"Molecular characterization and tissue distribution of ZO-2, a tight junction protein homologous to ZO-1 and the Drosophila discs-large tumor suppressor protein.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8132716","citation_count":398,"is_preprint":false},{"pmid":"10575001","id":"PMC_10575001","title":"Protein interactions at the tight junction. Actin has multiple binding partners, and ZO-1 forms independent complexes with ZO-2 and ZO-3.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10575001","citation_count":384,"is_preprint":false},{"pmid":"17087734","id":"PMC_17087734","title":"Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair.","date":"2006","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/17087734","citation_count":312,"is_preprint":false},{"pmid":"8421059","id":"PMC_8421059","title":"Monoclonal antibody 7H6 reacts with a novel tight junction-associated protein distinct from ZO-1, cingulin and ZO-2.","date":"1993","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8421059","citation_count":230,"is_preprint":false},{"pmid":"10613913","id":"PMC_10613913","title":"Cingulin contains globular and coiled-coil domains and interacts with ZO-1, ZO-2, ZO-3, and myosin.","date":"1999","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10613913","citation_count":229,"is_preprint":false},{"pmid":"12704386","id":"PMC_12704386","title":"Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12704386","citation_count":213,"is_preprint":false},{"pmid":"24614073","id":"PMC_24614073","title":"Mutations in TJP2 cause progressive cholestatic liver disease.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24614073","citation_count":207,"is_preprint":false},{"pmid":"20868367","id":"PMC_20868367","title":"Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling.","date":"2010","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/20868367","citation_count":173,"is_preprint":false},{"pmid":"12604349","id":"PMC_12604349","title":"Tyrosine phosphorylation of occludin attenuates its interactions with ZO-1, ZO-2, and ZO-3.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12604349","citation_count":156,"is_preprint":false},{"pmid":"18172007","id":"PMC_18172007","title":"Early embryonic lethality of mice lacking ZO-2, but Not ZO-3, reveals critical and nonredundant roles for individual zonula occludens proteins in mammalian development.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18172007","citation_count":153,"is_preprint":false},{"pmid":"11855865","id":"PMC_11855865","title":"Nuclear localization of the tight junction protein ZO-2 in epithelial cells.","date":"2002","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/11855865","citation_count":152,"is_preprint":false},{"pmid":"14720506","id":"PMC_14720506","title":"The tight junction protein ZO-2 associates with Jun, Fos and C/EBP transcription factors in epithelial cells.","date":"2004","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/14720506","citation_count":134,"is_preprint":false},{"pmid":"12403786","id":"PMC_12403786","title":"The tight junction protein ZO-2 localizes to the nucleus and interacts with the heterogeneous nuclear ribonucleoprotein scaffold attachment factor-B.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12403786","citation_count":131,"is_preprint":false},{"pmid":"10874042","id":"PMC_10874042","title":"Characterization of the interaction between protein 4.1R and ZO-2. A possible link between the tight junction and the actin cytoskeleton.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10874042","citation_count":125,"is_preprint":false},{"pmid":"10844608","id":"PMC_10844608","title":"Tight junction proteins ZO-1, ZO-2, and occludin along isolated renal tubules.","date":"2000","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/10844608","citation_count":112,"is_preprint":false},{"pmid":"28924228","id":"PMC_28924228","title":"An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28924228","citation_count":107,"is_preprint":false},{"pmid":"9620290","id":"PMC_9620290","title":"Subcellular distribution of tight junction-associated proteins (occludin, ZO-1, ZO-2) in rodent skin.","date":"1998","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9620290","citation_count":107,"is_preprint":false},{"pmid":"23885123","id":"PMC_23885123","title":"JAM-A associates with ZO-2, afadin, and PDZ-GEF1 to activate Rap2c and regulate epithelial barrier function.","date":"2013","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/23885123","citation_count":103,"is_preprint":false},{"pmid":"8824195","id":"PMC_8824195","title":"The tight junction protein ZO-2 contains three PDZ (PSD-95/Discs-Large/ZO-1) domains and an alternatively spliced region.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8824195","citation_count":91,"is_preprint":false},{"pmid":"19538286","id":"PMC_19538286","title":"Roles of ZO-1 and ZO-2 in establishment of the belt-like adherens and tight junctions with paracellular permselective barrier function.","date":"2009","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19538286","citation_count":87,"is_preprint":false},{"pmid":"20602916","id":"PMC_20602916","title":"Genomic duplication and overexpression of TJP2/ZO-2 leads to altered expression of apoptosis genes in progressive nonsyndromic hearing loss DFNA51.","date":"2010","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20602916","citation_count":83,"is_preprint":false},{"pmid":"15456900","id":"PMC_15456900","title":"Association of ARVCF with zonula occludens (ZO)-1 and ZO-2: binding to PDZ-domain proteins and cell-cell adhesion regulate plasma membrane and nuclear localization of ARVCF.","date":"2004","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/15456900","citation_count":81,"is_preprint":false},{"pmid":"17374535","id":"PMC_17374535","title":"ZO-2 silencing in epithelial cells perturbs the gate and fence function of tight junctions and leads to an atypical monolayer architecture.","date":"2007","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/17374535","citation_count":79,"is_preprint":false},{"pmid":"17881732","id":"PMC_17881732","title":"Cyclin D1 is transcriptionally down-regulated by ZO-2 via an E box and the transcription factor c-Myc.","date":"2007","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/17881732","citation_count":79,"is_preprint":false},{"pmid":"11598001","id":"PMC_11598001","title":"Link of the unique oncogenic properties of adenovirus type 9 E4-ORF1 to a select interaction with the candidate tumor suppressor protein ZO-2.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11598001","citation_count":76,"is_preprint":false},{"pmid":"15194440","id":"PMC_15194440","title":"Characterization of the tight junction protein ZO-2 localized at the nucleus of epithelial cells.","date":"2004","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15194440","citation_count":71,"is_preprint":false},{"pmid":"19148554","id":"PMC_19148554","title":"Angiopoietin-1 reduces vascular endothelial growth factor-induced brain endothelial permeability via upregulation of ZO-2.","date":"2009","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19148554","citation_count":67,"is_preprint":false},{"pmid":"17217619","id":"PMC_17217619","title":"Altered expression of ZO-1 and ZO-2 in Sertoli cells and loss of blood-testis barrier integrity in testicular carcinoma in situ.","date":"2006","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/17217619","citation_count":66,"is_preprint":false},{"pmid":"20970449","id":"PMC_20970449","title":"Assessments of tight junction proteins occludin, claudin 5 and scaffold proteins ZO1 and ZO2 in endothelial cells of the rat blood-brain barrier: cellular responses to neurotoxicants malathion and lead acetate.","date":"2010","source":"Neurotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/20970449","citation_count":63,"is_preprint":false},{"pmid":"11018256","id":"PMC_11018256","title":"Organization and expression of the human zo-2 gene (tjp-2) in normal and neoplastic tissues.","date":"2000","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11018256","citation_count":63,"is_preprint":false},{"pmid":"15975580","id":"PMC_15975580","title":"hScrib interacts with ZO-2 at the cell-cell junctions of epithelial cells.","date":"2005","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15975580","citation_count":62,"is_preprint":false},{"pmid":"18596233","id":"PMC_18596233","title":"ZO-1- and ZO-2-dependent integration of myosin-2 to epithelial zonula adherens.","date":"2008","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/18596233","citation_count":60,"is_preprint":false},{"pmid":"26451340","id":"PMC_26451340","title":"Mutations in TJP2, encoding zona occludens 2, and liver disease.","date":"2015","source":"Tissue barriers","url":"https://pubmed.ncbi.nlm.nih.gov/26451340","citation_count":50,"is_preprint":false},{"pmid":"18775424","id":"PMC_18775424","title":"Heterocellular interaction enhances recruitment of alpha and beta-catenins and ZO-2 into functional gap-junction complexes and induces gap junction-dependant differentiation of mammary epithelial cells.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18775424","citation_count":49,"is_preprint":false},{"pmid":"29238877","id":"PMC_29238877","title":"Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing.","date":"2017","source":"Journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/29238877","citation_count":48,"is_preprint":false},{"pmid":"10360833","id":"PMC_10360833","title":"Tight junction protein ZO-2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma.","date":"1999","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10360833","citation_count":48,"is_preprint":false},{"pmid":"27009203","id":"PMC_27009203","title":"ZO-2 silencing induces renal hypertrophy through a cell cycle mechanism and the activation of YAP and the mTOR pathway.","date":"2016","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/27009203","citation_count":47,"is_preprint":false},{"pmid":"17632043","id":"PMC_17632043","title":"Identification, tissue distribution and developmental expression of tjp1/zo-1, tjp2/zo-2 and tjp3/zo-3 in the zebrafish, Danio rerio.","date":"2007","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/17632043","citation_count":39,"is_preprint":false},{"pmid":"18817772","id":"PMC_18817772","title":"Tight junction protein ZO-2 expression and relative function of ZO-1 and ZO-2 during mouse blastocyst formation.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18817772","citation_count":36,"is_preprint":false},{"pmid":"16920099","id":"PMC_16920099","title":"The tight junction protein ZO-2 has several functional nuclear export signals.","date":"2006","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16920099","citation_count":35,"is_preprint":false},{"pmid":"33465371","id":"PMC_33465371","title":"Protective Functions of ZO-2/Tjp2 Expressed in Hepatocytes and Cholangiocytes Against Liver Injury and Cholestasis.","date":"2021","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/33465371","citation_count":31,"is_preprint":false},{"pmid":"22671599","id":"PMC_22671599","title":"ZO-2, a tight junction scaffold protein involved in the regulation of cell proliferation and apoptosis.","date":"2012","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22671599","citation_count":28,"is_preprint":false},{"pmid":"24905925","id":"PMC_24905925","title":"ZO-1 and ZO-2 are required for extra-embryonic endoderm integrity, primitive ectoderm survival and normal cavitation in embryoid bodies derived from mouse embryonic stem cells.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24905925","citation_count":26,"is_preprint":false},{"pmid":"18197414","id":"PMC_18197414","title":"Bile duct ligation in the rat causes upregulation of ZO-2 and decreased colocalization of claudins with ZO-1 and occludin.","date":"2008","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18197414","citation_count":26,"is_preprint":false},{"pmid":"31696999","id":"PMC_31696999","title":"TJP2 hepatobiliary disorders: Novel variants and clinical diversity.","date":"2019","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/31696999","citation_count":25,"is_preprint":false},{"pmid":"29845705","id":"PMC_29845705","title":"Effects of the differential expression of ZO-1 and ZO-2 on podocyte structure and function.","date":"2018","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/29845705","citation_count":24,"is_preprint":false},{"pmid":"23826934","id":"PMC_23826934","title":"Sorting nexin 27 (SNX27) associates with zonula occludens-2 (ZO-2) and modulates the epithelial tight junction.","date":"2013","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/23826934","citation_count":24,"is_preprint":false},{"pmid":"10495427","id":"PMC_10495427","title":"zo-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells.","date":"1999","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10495427","citation_count":22,"is_preprint":false},{"pmid":"30291936","id":"PMC_30291936","title":"The organophosphate pesticide methamidophos opens the blood-testis barrier and covalently binds to ZO-2 in mice.","date":"2018","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30291936","citation_count":22,"is_preprint":false},{"pmid":"19538296","id":"PMC_19538296","title":"The tight junction protein ZO-2 blocks cell cycle progression and inhibits cyclin D1 expression.","date":"2009","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19538296","citation_count":21,"is_preprint":false},{"pmid":"26668150","id":"PMC_26668150","title":"Identification of Two Disease-causing Genes TJP2 and GJB2 in a Chinese Family with Unconditional Autosomal Dominant Nonsyndromic Hereditary Hearing Impairment.","date":"2015","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/26668150","citation_count":20,"is_preprint":false},{"pmid":"23948304","id":"PMC_23948304","title":"Papillomavirus E6 oncoprotein up-regulates occludin and ZO-2 expression in ovariectomized mice epidermis.","date":"2013","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/23948304","citation_count":19,"is_preprint":false},{"pmid":"30658709","id":"PMC_30658709","title":"Novel compound heterozygote mutations of TJP2 in a Chinese child with progressive cholestatic liver disease.","date":"2019","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30658709","citation_count":19,"is_preprint":false},{"pmid":"25486565","id":"PMC_25486565","title":"Different effects of ZO-1, ZO-2 and ZO-3 silencing on kidney collecting duct principal cell proliferation and adhesion.","date":"2014","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/25486565","citation_count":18,"is_preprint":false},{"pmid":"27604867","id":"PMC_27604867","title":"SUMOylation regulates the intracellular fate of ZO-2.","date":"2016","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/27604867","citation_count":17,"is_preprint":false},{"pmid":"31318316","id":"PMC_31318316","title":"Activation of the Ca2+ sensing receptor and the PKC/WNK4 downstream signaling cascade induces incorporation of ZO-2 to tight junctions and its separation from 14-3-3.","date":"2019","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/31318316","citation_count":16,"is_preprint":false},{"pmid":"24665396","id":"PMC_24665396","title":"Beyond cell-cell adhesion: Emerging roles of the tight junction scaffold ZO-2.","date":"2013","source":"Tissue barriers","url":"https://pubmed.ncbi.nlm.nih.gov/24665396","citation_count":14,"is_preprint":false},{"pmid":"19380416","id":"PMC_19380416","title":"The tight junction protein ZO-2 mediates proliferation of vascular smooth muscle cells via regulation of Stat1.","date":"2009","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/19380416","citation_count":14,"is_preprint":false},{"pmid":"37499899","id":"PMC_37499899","title":"Treatment with an ileal bile acid transporter inhibitor in patients with TJP2 deficiency.","date":"2023","source":"Clinics and research in hepatology and gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/37499899","citation_count":13,"is_preprint":false},{"pmid":"28983606","id":"PMC_28983606","title":"PARP‑1 may be involved in hydroquinone‑induced apoptosis by poly ADP‑ribosylation of ZO‑2.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28983606","citation_count":13,"is_preprint":false},{"pmid":"9837755","id":"PMC_9837755","title":"Protein-binding domains of the tight junction protein, ZO-2, are highly conserved between avian and mammalian species.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9837755","citation_count":13,"is_preprint":false},{"pmid":"36966163","id":"PMC_36966163","title":"ZNF582 overexpression restrains the progression of clear cell renal cell carcinoma by enhancing the binding of TJP2 and ERK2 and inhibiting ERK2 phosphorylation.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36966163","citation_count":12,"is_preprint":false},{"pmid":"23612256","id":"PMC_23612256","title":"Alu-related transcript of TJP2 gene as a marker for colorectal cancer.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23612256","citation_count":12,"is_preprint":false},{"pmid":"12645256","id":"PMC_12645256","title":"[LIM protein KyoT2 interacts with human tight junction protein ZO-2-i3].","date":"2002","source":"Yi chuan xue bao = Acta genetica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/12645256","citation_count":12,"is_preprint":false},{"pmid":"34689705","id":"PMC_34689705","title":"ZO-2 favors Hippo signaling, and its re-expression in the steatotic liver by AMPK restores junctional sealing.","date":"2021","source":"Tissue barriers","url":"https://pubmed.ncbi.nlm.nih.gov/34689705","citation_count":11,"is_preprint":false},{"pmid":"37240145","id":"PMC_37240145","title":"GNAQ-Regulated ZO-1 and ZO-2 Act as Tumor Suppressors by Modulating EMT Potential and Tumor-Repressive Microenvironment in Lung Cancer.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37240145","citation_count":11,"is_preprint":false},{"pmid":"36151109","id":"PMC_36151109","title":"ZO-2/Tjp2 suppresses Yap and Wwtr1/Taz-mediated hepatocyte to cholangiocyte transdifferentiation in the mouse liver.","date":"2022","source":"NPJ Regenerative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36151109","citation_count":10,"is_preprint":false},{"pmid":"34010016","id":"PMC_34010016","title":"Tight junction protein ZO-2 modulates the nuclear accumulation of transcription factor TEAD.","date":"2021","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/34010016","citation_count":10,"is_preprint":false},{"pmid":"21679692","id":"PMC_21679692","title":"The tight junction protein ZO-2 and Janus kinase 1 mediate intercellular communications in vascular smooth muscle cells.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21679692","citation_count":10,"is_preprint":false},{"pmid":"34504838","id":"PMC_34504838","title":"Two Novel Pathogenic Variants of TJP2 Gene and the Underlying Molecular Mechanisms in Progressive Familial Intrahepatic Cholestasis Type 4 Patients.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34504838","citation_count":9,"is_preprint":false},{"pmid":"27398226","id":"PMC_27398226","title":"Chronic hypoxia down-regulates tight junction protein ZO-2 expression in children with cyanotic congenital heart defect.","date":"2015","source":"ESC heart failure","url":"https://pubmed.ncbi.nlm.nih.gov/27398226","citation_count":9,"is_preprint":false},{"pmid":"12507281","id":"PMC_12507281","title":"Dynamic assembly of tight junction-associated proteins ZO-1, ZO-2, ZO-3 and occludin during mouse tooth development.","date":"2003","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/12507281","citation_count":9,"is_preprint":false},{"pmid":"30713254","id":"PMC_30713254","title":"ZO-2 Suppresses Cell Migration Mediated by a Reduction in Matrix Metalloproteinase 2 in Claudin-18-Expressing Lung Adenocarcinoma A549 Cells.","date":"2019","source":"Biological & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/30713254","citation_count":8,"is_preprint":false},{"pmid":"38473701","id":"PMC_38473701","title":"The Role of ZO-2 in Modulating JAM-A and γ-Actin Junctional Recruitment, Apical Membrane and Tight Junction Tension, and Cell Response to Substrate Stiffness and Topography.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38473701","citation_count":8,"is_preprint":false},{"pmid":"38447037","id":"PMC_38447037","title":"Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis.","date":"2024","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/38447037","citation_count":6,"is_preprint":false},{"pmid":"37578083","id":"PMC_37578083","title":"Silenced LASP1 interacts with DNMT1 to promote TJP2 expression and attenuate articular cartilage injury in mice by suppressing TJP2 methylation.","date":"2023","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37578083","citation_count":4,"is_preprint":false},{"pmid":"39462647","id":"PMC_39462647","title":"A ZO-2 scaffolding mechanism regulates the Hippo signalling pathway.","date":"2024","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/39462647","citation_count":4,"is_preprint":false},{"pmid":"37995182","id":"PMC_37995182","title":"p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor-suppressor function mediated by p190A RhoGAP.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37995182","citation_count":4,"is_preprint":false},{"pmid":"36291162","id":"PMC_36291162","title":"Polyubiquitination and SUMOylation Sites Regulate the Stability of ZO-2 Protein and the Sealing of Tight Junctions.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36291162","citation_count":4,"is_preprint":false},{"pmid":"38138924","id":"PMC_38138924","title":"Transcriptomic Analysis of Tight Junction Proteins Demonstrates the Aberrant Expression and Function of Zona Occludens 2 (ZO-2) Protein in Stanford Type A Aortic Dissection.","date":"2023","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38138924","citation_count":3,"is_preprint":false},{"pmid":"40247635","id":"PMC_40247635","title":"Rotenone inhibited osteosarcoma metastasis by modulating ZO-2 expression and location via the ROS/Ca2+/AMPK pathway.","date":"2025","source":"Redox report : communications in free radical research","url":"https://pubmed.ncbi.nlm.nih.gov/40247635","citation_count":2,"is_preprint":false},{"pmid":"37292741","id":"PMC_37292741","title":"p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor suppressor function mediated by p190A RhoGAP.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37292741","citation_count":2,"is_preprint":false},{"pmid":"26983395","id":"PMC_26983395","title":"[Progressive familial intrahepatic cholestasis related to mutation of the TJP2 gene: recent advances].","date":"2016","source":"Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/26983395","citation_count":2,"is_preprint":false},{"pmid":"39322562","id":"PMC_39322562","title":"Molecular alterations associated with pathophysiology in liver-specific ZO-1 and ZO-2 knockout mice.","date":"2024","source":"Cell structure and function","url":"https://pubmed.ncbi.nlm.nih.gov/39322562","citation_count":1,"is_preprint":false},{"pmid":"37205944","id":"PMC_37205944","title":"Case Report: A Novel Single Variant TJP2 Mutation in a Case of Benign Recurrent Intrahepatic Cholestasis.","date":"2021","source":"JPGN reports","url":"https://pubmed.ncbi.nlm.nih.gov/37205944","citation_count":1,"is_preprint":false},{"pmid":"41210963","id":"PMC_41210963","title":"ZO-1/Tjp1 and ZO-2/Tjp2 deletion in retinal pigment epithelium causes progressive retinal degeneration.","date":"2025","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/41210963","citation_count":0,"is_preprint":false},{"pmid":"39910408","id":"PMC_39910408","title":"Contact and communication: ZO-2 and the Hippo pathway.","date":"2025","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/39910408","citation_count":0,"is_preprint":false},{"pmid":"41913267","id":"PMC_41913267","title":"RBM15 drives bladder cancer progression through YTHDF2-dependent m6A-mediated regulation of ZO2.","date":"2026","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/41913267","citation_count":0,"is_preprint":false},{"pmid":"40728639","id":"PMC_40728639","title":"ZO-2 is a scaffold at the centriole and mitotic spindle poles that enhances microtubule stability and supports the proper development of mitotic spindles and cilia.","date":"2025","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/40728639","citation_count":0,"is_preprint":false},{"pmid":"42082186","id":"PMC_42082186","title":"Simultaneous TFAM and TJP2 Variants in a Child With Cirrhosis and Hepatocellular Carcinoma.","date":"2026","source":"Pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/42082186","citation_count":0,"is_preprint":false},{"pmid":"41259016","id":"PMC_41259016","title":"c-Abl Kinase Targets Tight Junction Protein ZO-2 in Regulation of Cell Migration and Morphology.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/41259016","citation_count":0,"is_preprint":false},{"pmid":"41870046","id":"PMC_41870046","title":"ZO-2 determines cell membrane localization of receptor NTCP and supports hepatitis B virus infection.","date":"2026","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/41870046","citation_count":0,"is_preprint":false},{"pmid":"40251428","id":"PMC_40251428","title":"Report of a missense TJP2 variant associated to PFIC4 with a pronounced phenotypic variability: Focus on the structural effects on the protein level.","date":"2025","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40251428","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.01.10.632304","title":"Competitive elimination of ZO-1/ZO-2-deficient cells regulates epithelial barrier homeostasis","date":"2025-01-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.10.632304","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48374,"output_tokens":12003,"usd":0.162583,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":23156,"output_tokens":6306,"usd":0.136715,"stage2_stop_reason":"end_turn"},"total_usd":0.299298,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"ZO-2 (TJP2) was found to coimmunoprecipitate with ZO-1 from MDCK cell extracts, identifying it as a tight junction-associated peripheral membrane protein that interacts with ZO-1. ZO-2 contains a region homologous to ZO-1 including guanylate kinase-like and PDZ domains (MAGUK family). ZO-2 localizes exclusively at cytoplasmic surfaces of tight junctions in epithelia (liver, intestine, kidney, testis, arterial endothelium) but is absent from the fascia adherens in cardiac myocytes, unlike ZO-1.\",\n      \"method\": \"Coimmunoprecipitation from MDCK cells, polyclonal antibody against unique ZO-2 region, immunohistochemistry of frozen tissue sections, double-label immunofluorescence\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP plus immunolocalization across multiple tissues, foundational characterization paper replicated by subsequent work\",\n      \"pmids\": [\"8132716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"ZO-2 contains three PDZ domains, an SH3 domain, and a guanylate kinase-like domain. An alternatively spliced 36-amino acid domain exists in the C-terminal proline-rich region. The PDZ and protein-binding domains are highly conserved relative to ZO-1, while the C-terminal regions are divergent (25% identity), suggesting distinct functions.\",\n      \"method\": \"Full-length cDNA sequencing and sequence analysis of multiple ZO-2 cDNAs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Strong — comprehensive sequence characterization of a single protein, replicated by later structural studies, but primary method is cDNA analysis\",\n      \"pmids\": [\"8824195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ZO-2 binds directly to the COOH-terminal YV sequence of claudin-1 through -8 via its PDZ1 domain in vitro. In cells lacking ZO-1, ZO-2 is recruited to claudin-based networks through both PDZ2 (ZO-2)/PDZ2 (ZO-1) interactions and PDZ1 (ZO-2)/claudin-COOH interactions.\",\n      \"method\": \"In vitro binding assays with purified recombinant PDZ domains, transfection of claudins into L fibroblasts, immunofluorescence colocalization\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with recombinant proteins plus cell-based validation, independently replicated across multiple labs\",\n      \"pmids\": [\"10601346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ZO-2 directly binds F-actin in vitro (cosedimentation assay) but does not act as an F-actin cross-linking protein and does not bind actin filament ends. ZO-2 also directly binds ZO-1 and occludin. Immunoprecipitation showed ZO-1 and ZO-2 exist primarily as independent ZO-1·ZO-2 complexes rather than a trimeric ZO-1·ZO-2·ZO-3 complex in situ.\",\n      \"method\": \"Actin cosedimentation assays with purified recombinant proteins, low-speed sedimentation analyses, immunoprecipitation, immunofluorescence colocalization in cytochalasin D-treated MDCK cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro binding reconstitution plus immunoprecipitation in two orthogonal methods, single lab\",\n      \"pmids\": [\"10575001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The NH2-terminal fragment of cingulin (residues 1-378) interacts in vitro with ZO-2 in pull-down assays from epithelial lysates. ZO-2 immunoprecipitates contain cingulin, confirming an in vivo interaction.\",\n      \"method\": \"Pull-down assays from epithelial and insect cell lysates, co-immunoprecipitation\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and pull-down, single lab, two orthogonal methods\",\n      \"pmids\": [\"10613913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Protein 4.1R isoforms (135 and 150 kDa) specifically interact with ZO-2 via residues encoded by exons 19-21 of 4.1R and residues 1054-1118 of ZO-2, as determined by yeast two-hybrid, in vitro binding, and co-immunoprecipitation. 4.1R co-localizes with ZO-2 and occludin at MDCK tight junctions and co-precipitates with ZO-2, ZO-1, occludin, actin, and alpha-spectrin, suggesting 4.1R links the tight junction to the actin cytoskeleton through ZO-2.\",\n      \"method\": \"Yeast two-hybrid system, in vitro binding studies, immunocolocalization, immunoprecipitation, Western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus reciprocal co-IP plus in vitro binding, single lab, multiple orthogonal methods with domain mapping\",\n      \"pmids\": [\"10874042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Adenovirus type 9 E4-ORF1 oncoprotein selectively targets ZO-2 (acting as a candidate tumor suppressor). Complex formation is mediated by the C-terminal PDZ-binding motif of Ad9 E4-ORF1 and the first PDZ domain of ZO-2. This interaction results in aberrant cytoplasmic sequestration of ZO-2. Overexpression of wild-type ZO-2 (but not mutant ZO-2 lacking PDZ2 and PDZ3) interfered with Ad9 E4-ORF1-induced focus formation.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence colocalization, focus formation assay, ZO-2 overexpression/mutant rescue experiments\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus functional rescue with domain-mapping mutants, single lab\",\n      \"pmids\": [\"11598001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ZO-2 localizes to the nucleus in sparse epithelial cultures, accumulating in clusters that partially colocalize with splicing factor SC35. Nuclear staining diminishes as cultures reach confluence. Nuclear-to-cytoplasm shuttling is sensitive to leptomycin B (nuclear export inhibitor) and is mediated by the actin cytoskeleton. ZO-2 shuttling to the nucleus uses a pre-existing pool, not newly synthesized protein.\",\n      \"method\": \"Immunofluorescence in MDCK cells at varying confluence, leptomycin B treatment, mechanical injury assay, cell-cell contact disruption, protein synthesis inhibition\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiments with multiple pharmacological perturbations, single lab\",\n      \"pmids\": [\"11855865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Nuclear ZO-2 directly interacts with the DNA-binding protein scaffold attachment factor-B (SAF-B) via its PDZ1 domain, as shown by yeast two-hybrid assays and in vivo co-immunoprecipitation. EGFP-ZO-2 and DsRed-SAF-B fusion proteins partially co-localize in nuclei of transfected epithelial cells. No association of SAF-B with ZO-1 was found.\",\n      \"method\": \"Yeast two-hybrid assay, co-immunoprecipitation from epithelial cells, confocal microscopy of fluorescently-tagged fusion proteins\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus co-IP in cells, single lab, two orthogonal methods\",\n      \"pmids\": [\"12403786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A mutation in the first PDZ domain of TJP2/ZO-2 (associated with familial hypercholanemia in Amish individuals) reduces PDZ1 domain stability and ligand binding in vitro. Hepatic tight junctions show a morphological change in individuals with this mutation.\",\n      \"method\": \"In vitro domain stability and ligand binding assays with recombinant PDZ1 domain mutant, electron microscopy of liver biopsies\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Weak — in vitro biochemical assay on isolated domain plus structural microscopy, single study\",\n      \"pmids\": [\"12704386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Tyrosine phosphorylation of the C-terminal tail of occludin (by c-Src in vitro) markedly reduces its binding to ZO-2 (as well as ZO-1 and ZO-3), but does not affect occludin binding to F-actin.\",\n      \"method\": \"In vitro phosphorylation of GST-fused C-occludin by c-Src, in vitro binding assays with ZO-2\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstituted kinase assay with mutagenesis-equivalent phosphomimetic approach, single lab, single method\",\n      \"pmids\": [\"12604349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ZO-2 associates with transcription factors Jun, Fos, and C/EBP both at the nucleus and at tight junction regions of epithelial cells. This association was confirmed by pull-down assays, gel shift analysis, and co-immunoprecipitation. ZO-2 down-regulates AP-1-controlled gene transcription in a dose-dependent manner; both the amino and carboxyl domains of ZO-2 are capable of inhibiting gene transcription.\",\n      \"method\": \"Pull-down assays with ZO-2 GST fusion proteins, gel shift (EMSA), co-immunoprecipitation, immunolocalization, CAT reporter gene assays\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pull-down plus co-IP plus functional reporter assay, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"14720506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ZO-2 is present in the nuclear matrix and co-immunoprecipitates with lamin B1 and actin from nuclei of sparse cultures. ZO-2 contains multiple nuclear localization signals (NLS) at its amino region; deletion of these NLS diminishes nuclear import and impairs the ability to regulate AP-1-controlled transcriptional activity. ZO-2 contains a functional nuclear export signal (NES2) at the GK region that is leptomycin B-sensitive.\",\n      \"method\": \"Nuclear fractionation, co-immunoprecipitation from nuclear fractions, NLS deletion mutants transfection, nuclear export assay with ovalbumin-conjugated NES peptides, leptomycin B sensitivity, reporter gene assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — nuclear fractionation with co-IP plus functional NLS/NES mapping with multiple mutants, single lab\",\n      \"pmids\": [\"15194440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ARVCF interacts with ZO-2 via a C-terminal PDZ-binding motif on ARVCF and the PDZ domains of ZO-2. Nuclear localization of ARVCF is dependent on this PDZ-binding motif and can be mediated specifically by the PDZ domains of ZO-2 (but not equivalently by ZO-1). Disruption of cell-cell adhesion releases ARVCF from the plasma membrane, with an increased fraction localizing to the nucleus.\",\n      \"method\": \"Co-immunoprecipitation, yeast two-hybrid, fluorescence microscopy, domain-mapping using PDZ-binding motif mutants, calcium-switch assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus functional rescue with domain mutants, single lab\",\n      \"pmids\": [\"15456900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"hScrib (mammalian Scribble homolog) directly interacts with ZO-2 via two PDZ domains of hScrib and the C-terminal PDZ-binding motif of ZO-2. Both proteins colocalize at cell-cell junctions. A point mutation in the LRR of hScrib delocalizes it from the plasma membrane and abrogates the interaction with ZO-2.\",\n      \"method\": \"GST pull-down, co-immunoprecipitation, immunofluorescence colocalization, LRR point-mutant analysis\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pull-down plus co-IP plus domain mapping mutants, single lab\",\n      \"pmids\": [\"15975580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ZO-1 and ZO-2 independently determine where claudins are polymerized during tight junction strand formation. In cells lacking both ZO-1 and ZO-2 (ZO-1 knockout/ZO-2 knockdown), tight junctions are completely absent despite normal cell polarity. Re-expression of either ZO-1 or ZO-2 alone restores claudin polymerization and tight junction formation. A truncated ZO-1 containing only PDZ1-3 was insufficient; forced membrane recruitment and dimerization of this truncated form restored claudin polymerization.\",\n      \"method\": \"Homologous recombination, RNAi knockdown, exogenous rescue by transfection, immunofluorescence, transepithelial resistance measurement\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO/KD with domain-mapping rescue experiments, multiple orthogonal methods, high-impact independent study\",\n      \"pmids\": [\"16923393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ZO-2 contains four nuclear export signals (NES-0, NES-1 in PDZ2; NES-2, NES-3 in GK region). NES-0 and NES-3 are functional and leptomycin B-sensitive. NES-1, previously thought non-functional, becomes active upon acquisition of negative charge at Ser369. Efficient nuclear exit of ZO-2 amino and middle segments requires paired NES; mutation of any single NES in full-length ZO-2 induces nuclear accumulation.\",\n      \"method\": \"Nuclear export assay using ovalbumin-conjugated NES peptides microinjected into nuclei of MDCK cells, leptomycin B sensitivity, transfection of full-length ZO-2 NES mutants\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional nuclear export assay with multiple NES mutants, single lab\",\n      \"pmids\": [\"16920099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ZO-2 silencing in MDCK cells increases paracellular permeability to dextran (gate function impairment), disrupts fence function (non-polarized E-cadherin distribution), decreases occludin and E-cadherin protein levels, delays arrival of ZO-1, occludin and E-cadherin to the plasma membrane during calcium switch, and produces atypical monolayer architecture with widened intercellular spaces, multistratification, and altered actin patterns.\",\n      \"method\": \"siRNA knockdown in MDCK cells, transepithelial electrical resistance measurement, dextran flux assay, calcium switch assay, immunofluorescence, Western blot\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean siRNA KD with multiple functional phenotypic readouts, single lab\",\n      \"pmids\": [\"17374535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ZO-2 down-regulates cyclin D1 transcription in a dose-dependent manner via an E box in the cyclin D1 promoter, reducing cell proliferation. ZO-2 does not directly bind DNA but recruits c-Myc (confirmed by EMSA, ChIP, and co-immunoprecipitation) and HDAC1 to the E box. HDAC activity is required for ZO-2-mediated repression.\",\n      \"method\": \"CAT reporter gene assays with cyclin D1 promoter deletions, EMSA, chromatin immunoprecipitation (ChIP), co-immunoprecipitation, HDAC inhibitor treatment, wound-healing proliferation assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (reporter, EMSA, ChIP, co-IP) in single lab establishing mechanism of cyclin D1 repression\",\n      \"pmids\": [\"17881732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ZO-2 knockout mice die shortly after implantation due to arrest in early gastrulation, demonstrating a non-redundant and critical role of ZO-2 in mammalian development. ZO-2−/− embryos show decreased proliferation at E6.5, increased apoptosis at E7.5, altered apical junctional complex architecture, and increased paracellular permeability. ZO-3 knockout mice have no obvious phenotype, indicating ZO-3 is dispensable.\",\n      \"method\": \"Gene targeting (ZO-2 and ZO-3 knockout mice), embryo histology and immunohistochemistry, paracellular tracer permeability assay, TUNEL/BrdU assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean in vivo genetic KO with multiple phenotypic readouts including barrier function measurement\",\n      \"pmids\": [\"18172007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ZO-1 and ZO-2 are both required for integration of myosin-2 into the epithelial zonula adherens (ZA). In ZO-1/ZO-2 double-depleted cells, a fragmented adherens junction (prezonula-AJ) positive for E-cadherin and actin but negative for myosin-2 forms. Re-expression of full-length ZO-1 or ZO-2 (or ZO-1 lacking PDZ1/2 but not PDZ1/2/3) restores myosin-2 integration. ZO-1/ZO-2 regulate RhoA-dependent spatiotemporal Rho activation for ZA establishment.\",\n      \"method\": \"Conditional ZO-1 KO/ZO-2 KD cell lines, rescue by transfection of truncation mutants, immunofluorescence, FRET analysis of Rho activation, dominant-active RhoA/ROCK transfection\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic depletion plus domain-mapping rescue plus FRET-based signaling readout, multiple orthogonal methods\",\n      \"pmids\": [\"18596233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In mouse preimplantation embryos, ZO-2 is expressed from both maternal and embryonic genomes; maternal ZO-2 protein associates with nuclei in zygotes and early cleavage stages. ZO-2 siRNA knockdown in zygotes delayed blastocoel cavity formation but did not block cell proliferation. ZO-2-deficient embryos compensatorily increased ZO-1 (but not occludin) assembly at tight junctions.\",\n      \"method\": \"siRNA microinjection into mouse zygotes/2-cell embryos, immunofluorescence, quantitative junctional analysis, blastocoel measurement\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA KD in embryos with functional blastocoel formation readout, single lab\",\n      \"pmids\": [\"18817772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ZO-2 uses its first PDZ domain to form a complex with YAP2. Endogenous ZO-2 and YAP2 co-localize in the nucleus. ZO-2 facilitates the nuclear localization and pro-apoptotic function of YAP2 in a PDZ-domain-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, co-localization by immunofluorescence, PDZ-domain deletion mutant analysis, nuclear localization and apoptosis assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with domain-mapping mutants and functional nuclear localization/apoptosis readout, single lab\",\n      \"pmids\": [\"20868367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Genomic duplication of TJP2 in a family with progressive nonsyndromic hearing loss DFNA51 leads to overexpression of TJP2 transcript and protein. TJP2 overexpression in affected family members leads to decreased phosphorylation of GSK-3β and altered expression of apoptosis-regulating genes, suggesting a mechanism for progressive hair cell death.\",\n      \"method\": \"SNP array genomic analysis, RT-PCR, Western blot, immunohistochemistry of inner ear tissue, phospho-GSK-3β Western blot, expression profiling of apoptosis genes\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genomic, molecular, and signaling characterization in patient cells, single study\",\n      \"pmids\": [\"20602916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"JAM-A directly associates with ZO-2 (and indirectly with afadin), and this complex together with PDZ-GEF1 activates the small GTPase Rap2c. siRNA-mediated downregulation of JAM-A, ZO-2, afadin, or PDZ-GEF1 results in enhanced epithelial permeability, indicating ZO-2 is a functional component of the JAM-A/afadin/PDZ-GEF1/Rap2c signaling module that regulates barrier function.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, transepithelial resistance and permeability assays, GTPase activity assays\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus siRNA KD with functional barrier readout, single lab\",\n      \"pmids\": [\"23885123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SNX27 interacts with ZO-2 via the PDZ domain of SNX27 and the C-terminal PDZ-binding motif of ZO-2. Upon tight junction disruption by calcium chelation, ZO-2 transiently localizes to SNX27-positive early endosomes. SNX27 depletion decreases ZO-2 (but not ZO-1) mobility at cell-cell contacts (FRAP) and increases junctional permeability to large solutes.\",\n      \"method\": \"Proteomic interaction screen, co-immunoprecipitation, confocal immunofluorescence, FRAP, siRNA knockdown, permeability assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomic screen plus co-IP plus FRAP plus functional permeability readout, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"23826934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Protein-truncating mutations in TJP2 cause failure of protein localization to tight junctions and disruption of tight-junction structure, resulting in severe progressive cholestatic liver disease. This contrasts with embryonic-lethal knockout in mice, highlighting species and organ-specific redundancy differences.\",\n      \"method\": \"Next-generation sequencing, immunohistochemistry and electron microscopy of liver biopsies, protein localization studies in patient tissue\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct demonstration of protein mislocalization caused by truncating mutations in patient tissue, replicated across multiple patients\",\n      \"pmids\": [\"24614073\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZO-2 silencing in MDCK renal epithelial cells induces cell hypertrophy via two mechanisms: (1) prolonging G1 phase due to elevated cyclin D1, and (2) augmenting protein synthesis via nuclear accumulation and increased transcriptional activity of YAP, which decreases PTEN expression, elevating PIP3 and activating Akt/mTOR/S6K1 signaling. In uninephrectomized rats, compensatory renal hypertrophy is accompanied by decreased ZO-2 and nuclear YAP expression.\",\n      \"method\": \"siRNA knockdown in MDCK cells, cell cycle analysis, protein synthesis measurement, YAP localization and activity assays, PTEN/Akt/mTOR/S6K1 Western blot, uninephrectomy rat model, immunofluorescence\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA KD with multiple orthogonal functional readouts (cell cycle, protein synthesis, signaling pathway) plus in vivo rat model, single lab\",\n      \"pmids\": [\"27009203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZO-2 is SUMOylated by the SUMO machinery; it associates with E2 SUMO-conjugating enzyme Ubc9 and SUMO-deconjugating proteases SENP1 and SENP3. SUMOylation site K730 in human ZO-2 (GuK domain) was identified; mutation K730R results in prolonged nuclear localization. A construct mimicking constitutive SUMOylation (SUMO1ΔGG-ZO-2) localizes preferentially to the cytoplasm. ZO-2 directly binds GSK3β, and cytosolic SUMO1ΔGG-ZO-2 modulates GSK3β kinase activity. ZO-2 also forms a complex with β-catenin, and wild-type ZO-2 inhibits β-catenin/TCF-4 transcriptional activity.\",\n      \"method\": \"Co-immunoprecipitation, Ubc9 fusion-directed SUMOylation, SENP1 inhibition assays, site-directed mutagenesis (K730R), nuclear recruitment assay, reporter gene assay, GSK3β kinase activity assay\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (co-IP, SUMOylation assay, mutagenesis, kinase assay, reporter), single lab\",\n      \"pmids\": [\"27604867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The organophosphate pesticide methamidophos (MET) forms covalent bonds with ZO-2 at serine, tyrosine, and lysine residues. MET induces phosphorylation of ZO-2 and reduces the interaction between ZO-2 and occludin. MET targets ubiquitination sites on ZO-2 (including a lysine residue), and mutation of a MET-target lysine residue in ZO-2 interferes with TJ sealing in epithelial cells.\",\n      \"method\": \"Mass spectrometry (covalent modification identification), co-immunoprecipitation, Western blot (phosphorylation), transfection of ZO-2 mutants into epithelial cells, transepithelial resistance measurement\",\n      \"journal\": \"Toxicology and applied pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mass spectrometry identification of covalent modification sites plus functional mutagenesis rescue, single lab\",\n      \"pmids\": [\"30291936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CaSR activation by Gd3+ triggers ZO-2 concentration at tight junctions via PKC activation, which phosphorylates and activates WNK4, which in turn phosphorylates ZO-2, inducing its TJ localization. In low calcium, ZO-2 is protected from degradation by association with 14-3-3 proteins (ζ and σ). The ZO-2/14-3-3 complexes move to cell borders upon calcium restoration and then dissociate. The unique region 2 of ZO-2 and S261 (within an NLS) are critical for the interaction with 14-3-3 proteins and for efficient nuclear importation.\",\n      \"method\": \"Co-immunoprecipitation, pharmacological inhibition (CaSR agonist Gd3+, PKC/WNK4 inhibitors), site-directed mutagenesis (S261 and unique region 2 mutants), immunofluorescence, Western blot\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus pharmacological pathway dissection plus site-directed mutagenesis, single lab\",\n      \"pmids\": [\"31318316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZO-2 tight junction protein modulates nuclear accumulation of TEAD transcription factor. ZO-2 knockdown reduces nuclear TEAD; ZO-2 lacking NLS does not facilitate TEAD nuclear entry. Inhibition of nPKCδ in parental cells triggers cytoplasmic ZO-2/TEAD interaction and facilitates ZO-2/TEAD complex nuclear importation. nPKCε activates a ZO-2 nuclear export signal to enhance TEAD nuclear exit. ZO-2/TEAD interaction was confirmed by proximity ligation, co-immunoprecipitation, and pull-down assays.\",\n      \"method\": \"Proximity ligation assay, co-immunoprecipitation, pull-down assay, nPKCδ/ε inhibitor treatment, ZO-2 NLS mutant transfection, immunofluorescence of TEAD localization\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal interaction methods plus pharmacological pathway mapping plus functional nuclear localization readout, single lab\",\n      \"pmids\": [\"34010016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Liver-specific deletion of Tjp2 in mice results in lower claudin-1 protein levels, dilated canaliculi, lower microvilli density, aberrant radixin and BSEP (Abcb11) distribution, and mild progressive cholestasis with reduced Abcb11/Bsep and Cyp2b10 expression. Cholic acid diet causes severe cholestasis and liver necrosis in Tjp2-deficient mice. Combined hepatocyte and cholangiocyte deletion was necessary for severe CA-induced injury.\",\n      \"method\": \"Conditional liver-specific Cre-lox knockout (hepatocyte-specific and cholangiocyte-specific), electron microscopy, immunostaining, biochemical analysis, FITC-dextran permeability assay, cholic acid diet challenge\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional cell-type-specific KO with multiple functional and structural readouts, in vivo model\",\n      \"pmids\": [\"33465371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZO-2 associates with LATS1 (Hippo kinase), functioning as a scaffold for the Hippo pathway. ZO-2 silencing is accompanied by diminished LATS activity and nuclear concentration of YAP in renal epithelial cells, in uninephrectomized rat kidneys, and in liver steatosis in obese Zucker rats.\",\n      \"method\": \"Co-immunoprecipitation (ZO-2/LATS1), immunofluorescence of YAP localization, LATS kinase activity assay, siRNA knockdown, in vivo uninephrectomy rat model, obese Zucker rat model\",\n      \"journal\": \"Tissue barriers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus in vivo models plus siRNA KD with signaling readout, single lab\",\n      \"pmids\": [\"34689705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Liver-specific Tjp2 deletion in mice leads to DDC-diet-induced hepatocyte-to-cholangiocyte transdifferentiation, which is Yap/Wwtr1(Taz)-dependent and cell-autonomous to hepatocytes (not cholangiocytes). Tjp2 inactivation is sufficient to upregulate Yap and Taz protein expression in hepatocytes, but efficient transdifferentiation additionally requires the DDC-diet insult. Notch2 is not required.\",\n      \"method\": \"Conditional Tjp2 KO (hepatocyte-specific and cholangiocyte-specific), DDC diet challenge, Yap/Taz genetic inactivation experiments, immunostaining, lineage tracing\",\n      \"journal\": \"NPJ Regenerative medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific conditional KO with genetic epistasis (Yap/Taz), single lab\",\n      \"pmids\": [\"36151109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Residues K759 and K992 in human ZO-2 are acceptors for K48-linked polyubiquitination (targeting for proteasomal degradation); mutation to arginine increases ZO-2 half-life from ~20 to ~37 h. Residue K730 (the SUMOylation site) mutation increases ubiquitination and decreases ZO-2 half-life to ~6.7 h. Mutations at K759, K992, or K730 all decrease the TJ sealing peak (transepithelial resistance).\",\n      \"method\": \"Co-immunoprecipitation with ubiquitin antibodies, TUBE (tandem ubiquitin-binding entity) assay for K48-polyubiquitin, site-directed mutagenesis of K730, K759, K992, half-life measurement by cycloheximide chase, transepithelial resistance measurement\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — TUBE-based K48-ubiquitin identification plus mutagenesis plus functional TER readout, single lab\",\n      \"pmids\": [\"36291162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZNF582 binds to TJP2/ZO-2 protein and upregulates TJP2 protein expression. Increased TJP2 combines with ERK2 to promote ERK2 protein expression and suppresses phosphorylation of ERK2, thereby inhibiting ccRCC growth and metastasis.\",\n      \"method\": \"TMT quantitative proteomics, co-immunoprecipitation, Western blot, cell phenotype and orthotopic tumor experiments\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus proteomics plus functional oncology assays, single lab\",\n      \"pmids\": [\"36966163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"p190A RhoGAP interacts with ZO-2 in a manner dependent on RasGAP. Both RasGAP and ZO-2 are required for p190A to activate LATS kinases, elicit mesenchymal-to-epithelial transition, promote contact inhibition, suppress tumorigenesis, and transcriptionally modulate target genes. Low ARHGAP35 expression combined with high TJP2 expression predicts shorter survival.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown of ZO-2/RasGAP, LATS kinase activity assay, cell proliferation/contact inhibition assays, in vivo tumorigenesis models, reporter gene assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus siRNA KD with epistatic functional readouts, single lab\",\n      \"pmids\": [\"37995182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ZO-2 is required for contact-mediated inhibition of proliferation. ZO-2 acts as a scaffold that promotes LATS1-YAP interaction: ZO-2 binds LATS1 via its SH3 domain and YAP via its PDZ domains, thereby facilitating LATS1-mediated phosphorylation of YAP, leading to YAP cytoplasmic retention and inactivation. ZO-2 also promotes LATS1 stability.\",\n      \"method\": \"Co-immunoprecipitation with domain-specific ZO-2 mutants (SH3 and PDZ domain mutations), YAP phosphorylation assay, cell proliferation/contact inhibition assays, LATS1 stability measurement\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with domain-mapping mutants plus kinase activity and stability readout, single lab\",\n      \"pmids\": [\"39462647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ZO-2 loss reduces apical membrane rigidity (measured by AFM), inhibits γ-actin and JAM-A recruitment to the cell border, and facilitates p114RhoGEF and afadin accumulation at junctions, leading to increased TJ mechanical tension (measured by FRET ZO-1 tension probe) and increased tricellular TJ tension. ZO-2 KD cells show impaired responses to substrate stiffness and topography, and increased nuclear YAP and Snail.\",\n      \"method\": \"Atomic force microscopy, FRET tension probes (ZO-1 and E-cadherin), immunofluorescence, siRNA knockdown, AFM membrane rigidity measurement, nanostructured substrate assays\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — AFM plus FRET-based tension measurement plus immunofluorescence, single lab, multiple methods\",\n      \"pmids\": [\"38473701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZO-2 colocalizes with CEP164 at the distal appendage of the mother centriole and is present at mitotic spindle poles, the basal body of primary cilia, and the tail of spermatozoa. ZO-2 depletion inhibits astral and mitotic spindle microtubule (EB1-expressing) development, reduces KIF14 and TPX2 at spindle poles, increases NuMA accumulation, and decreases p-Aurora levels, leading to reduced spindle length, microtubule instability, and abnormal chromosome congression. ZO-2 co-immunoprecipitates with KIF14, NuMA, and p-Aurora; NuMA and Aurora-A bind different segments of ZO-2. ZO-2 depletion also reduces primary cilium development and blocks Sonic Hedgehog signaling.\",\n      \"method\": \"Co-immunoprecipitation with ZO-2 segments, immunofluorescence colocalization, siRNA knockdown, spindle length and morphology analysis, EB1 live imaging, SHH reporter assay\",\n      \"journal\": \"Cell and tissue research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus siRNA KD with multiple cellular phenotype readouts (spindle, cilia, signaling), single lab\",\n      \"pmids\": [\"40728639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"c-Abl kinase directly binds to and phosphorylates the C-terminus of ZO-2, and also stimulates JAK1, which subsequently phosphorylates the N-terminus of ZO-2. c-Abl regulates cellular morphology and migration through ZO-2 phosphorylation (demonstrated by RNAi knockdown/rescue strategy). c-Abl activity is associated with decreased traction forces on the substrate.\",\n      \"method\": \"In vitro kinase assay (c-Abl phosphorylation of ZO-2 C-terminus), immunoprecipitation of c-Abl/ZO-2 complex, RNAi knockdown/rescue, traction force microscopy, cell migration assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase assay plus RNAi rescue plus functional migration readout, single lab\",\n      \"pmids\": [\"41259016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"ZO-2 directly binds to NTCP (the HBV receptor sodium taurocholate cotransporting polypeptide), and this interaction is required for NTCP cell surface localization. ZO-2 knockdown or knockout decreases NTCP at the cell surface, reducing HBV attachment and infection. HBV surface protein preS1 binding causes dissociation of the NTCP/ZO-2 complex and formation of NTCP-preS1-actin complexes that internalize into cells. Actin polymerization is required for preS1 internalization and HBV infection (latrunculin A blocks this). ZO-1 and ZO-3 knockdown had no effect on HBV infection.\",\n      \"method\": \"Immunopurification/LC-MS/MS (interaction discovery), co-immunoprecipitation, ZO-2 KD/KO, NTCP cell surface flow cytometry, HBV infection assay, preS1 binding assay, latrunculin A treatment\",\n      \"journal\": \"mBio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomic interaction discovery plus co-IP plus KD/KO plus functional viral infection readout, single lab\",\n      \"pmids\": [\"41870046\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TJP2/ZO-2 is a MAGUK scaffold protein that physically links claudins (via PDZ1), occludin, JAM-A, and NTCP to the actin cytoskeleton at epithelial tight junctions, independently drives claudin polymerization and tight junction strand formation, undergoes regulated nuclear–cytoplasmic shuttling (controlled by NLS/NES sequences, SUMOylation at K730, ubiquitination at K759/K992, and 14-3-3 binding) where it represses AP-1/cyclin D1/YAP-TEAD transcription, scaffolds LATS1 to phosphorylate and inactivate YAP (Hippo pathway), and is also found at centrioles/spindle poles where it promotes microtubule stability; loss-of-function mutations in humans cause progressive cholestatic liver disease due to disrupted hepatocellular tight junction structure and impaired bile transporter localization.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TJP2 (ZO-2) is a MAGUK-family scaffold protein that organizes epithelial tight junctions and couples them to transcriptional and cytoskeletal control of cell growth [#0, #15]. As a tight junction-associated peripheral membrane protein bearing three PDZ domains, an SH3 domain, and a guanylate kinase-like domain, it directly binds claudins via PDZ1, ZO-1, occludin, and F-actin, physically linking transmembrane junction components to the cortical actin cytoskeleton [#1, #2, #3]. ZO-1 and ZO-2 independently determine where claudins polymerize into tight junction strands, and cells lacking both fail to form tight junctions altogether; either protein alone restores strand assembly [#15], and ZO-2 loss impairs both gate and fence functions and delays junctional protein recruitment [#17]. ZO-2 is essential in development, as its knockout causes peri-implantation embryonic lethality from gastrulation arrest [#19]. Beyond the junction, ZO-2 undergoes regulated nuclear-cytoplasmic shuttling governed by amino-terminal NLS sequences, multiple leptomycin B-sensitive nuclear export signals, SUMOylation at K730, K48-polyubiquitination at K759/K992, and 14-3-3 binding, which together tune its abundance and localization [#12, #16, #28, #35, #30]. In the nucleus it represses transcription, down-regulating AP-1 target genes and repressing cyclin D1 by recruiting c-Myc and HDAC1 to an E-box, thereby restraining proliferation [#11, #18]. ZO-2 acts as a Hippo-pathway scaffold, binding LATS1 through its SH3 domain and YAP through its PDZ domains to promote LATS1-mediated phosphorylation and cytoplasmic retention of YAP, enforcing contact inhibition of proliferation; its loss drives nuclear YAP/TEAD activity, PTEN suppression, Akt/mTOR signaling and cellular hypertrophy [#27, #33, #38, #31]. ZO-2 also localizes to centrioles and spindle poles, where it supports mitotic spindle microtubule stability and primary cilium formation [#40]. In humans, protein-truncating TJP2 mutations cause failure of tight-junction localization and progressive cholestatic liver disease, recapitulated by liver-specific deletion in mice that mislocalizes bile transporters and disrupts canalicular architecture [#26, #32].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established TJP2/ZO-2 as a distinct tight junction-associated MAGUK protein, answering whether it was a bona fide junctional component separate from ZO-1.\",\n      \"evidence\": \"Co-immunoprecipitation with ZO-1 from MDCK cells and immunolocalization across epithelial tissues\",\n      \"pmids\": [\"8132716\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding partners at the junction not yet mapped to specific domains\", \"Functional role beyond ZO-1 association unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined the modular domain architecture (three PDZ, SH3, GK domains) and divergent C-terminus, framing how ZO-2 might engage distinct ligands from ZO-1.\",\n      \"evidence\": \"Full-length cDNA sequencing and comparative sequence analysis\",\n      \"pmids\": [\"8824195\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional assignment of individual domains not tested\", \"Significance of the alternatively spliced region unresolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Resolved how ZO-2 bridges transmembrane junction proteins to the cytoskeleton, identifying claudin (PDZ1), ZO-1, occludin, F-actin, and cingulin as direct partners.\",\n      \"evidence\": \"In vitro binding with recombinant PDZ domains, actin cosedimentation, co-immunoprecipitation in MDCK and epithelial lysates\",\n      \"pmids\": [\"10601346\", \"10575001\", \"10613913\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and dynamics of the claudin/ZO complex in living strands not defined\", \"Whether ZO-2 actin binding is regulated unaddressed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Extended the cytoskeletal linkage by mapping a 4.1R/spectrin connection through a defined ZO-2 segment, reinforcing a tight-junction-to-actin scaffold.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro binding, co-immunoprecipitation, immunocolocalization in MDCK cells\",\n      \"pmids\": [\"10874042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of disrupting the 4.1R/ZO-2 link not tested\", \"Tissue-specificity of the interaction unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Revealed a non-junctional nuclear pool of ZO-2 that shuttles in a density- and export-dependent manner and binds nuclear partners, opening a transcriptional role.\",\n      \"evidence\": \"Confluence-dependent immunofluorescence, leptomycin B sensitivity, yeast two-hybrid and co-IP with SAF-B\",\n      \"pmids\": [\"11855865\", \"12403786\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptional output of nuclear ZO-2 not yet demonstrated\", \"Import/export signals not yet mapped\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined ZO-2 as a transcriptional repressor and mapped its NLS/NES shuttling determinants, linking junctional localization to gene control of AP-1 targets.\",\n      \"evidence\": \"Pull-down, EMSA, co-IP with Jun/Fos/C-EBP, reporter assays, nuclear fractionation and NLS/NES mutant analysis\",\n      \"pmids\": [\"14720506\", \"15194440\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct DNA binding excluded but full repressor complex undefined\", \"Physiological triggers of nuclear entry incomplete\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated that ZO-1 and ZO-2 are independently sufficient to drive claudin polymerization and tight-junction strand formation, establishing a core organizational function.\",\n      \"evidence\": \"ZO-1 KO/ZO-2 knockdown cells with domain-mapped rescue, immunofluorescence, TER measurement\",\n      \"pmids\": [\"16923393\", \"16920099\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which scaffolds template claudin polymerization not structurally defined\", \"Relative in vivo contributions of ZO-1 vs ZO-2 unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed ZO-2 controls both gate and fence functions and the kinetics of junctional protein assembly, and represses cyclin D1 to restrain proliferation, linking junction integrity to growth control.\",\n      \"evidence\": \"siRNA knockdown with TER/dextran flux/calcium switch assays; reporter, EMSA, ChIP and co-IP for cyclin D1 repression via c-Myc/HDAC1\",\n      \"pmids\": [\"17374535\", \"17881732\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How junctional vs nuclear pools coordinate growth signaling not dissected\", \"HDAC1 recruitment mechanism partial\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established the in vivo essentiality of ZO-2 (embryonic lethality) and its role in adherens junction maturation via RhoA-dependent myosin-2 integration.\",\n      \"evidence\": \"ZO-2 and ZO-3 knockout mice with histology/permeability assays; ZO-1/ZO-2 double-depletion with FRET Rho activation and rescue\",\n      \"pmids\": [\"18172007\", \"18596233\", \"18817772\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of gastrulation arrest unresolved\", \"Link between Rho regulation and junction defect mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected ZO-2 to YAP, showing PDZ1-dependent complex formation that modulates YAP nuclear localization and function, foreshadowing a Hippo-pathway role.\",\n      \"evidence\": \"Co-IP, colocalization, PDZ-deletion mutants, nuclear localization and apoptosis assays\",\n      \"pmids\": [\"20868367\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Context-dependence of pro- vs anti-growth YAP outcomes unclear\", \"Upstream Hippo kinase link not yet established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established TJP2 truncating mutations as a cause of human progressive cholestatic liver disease through failed junctional localization, defining a Mendelian disease link.\",\n      \"evidence\": \"Next-generation sequencing and patient liver biopsy immunohistochemistry/electron microscopy\",\n      \"pmids\": [\"24614073\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting junction disruption to bile transport not yet defined in vivo\", \"Species difference vs embryonic-lethal mouse unexplained\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked ZO-2 loss to cellular hypertrophy through dual cyclin D1 (G1) and YAP-PTEN-Akt/mTOR mechanisms, and mapped SUMOylation (K730) as a shuttling switch that also tunes GSK3-beta and beta-catenin signaling.\",\n      \"evidence\": \"siRNA knockdown with cell-cycle/protein-synthesis/signaling readouts and uninephrectomy rat model; Ubc9/SENP SUMOylation assays and K730R mutagenesis\",\n      \"pmids\": [\"27009203\", \"27604867\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct LATS link to YAP regulation not yet shown here\", \"How SUMO and other PTMs are integrated in vivo unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined PTM- and 14-3-3-controlled regulation of ZO-2 stability and localization downstream of calcium/CaSR-PKC-WNK4 signaling, explaining how junction assembly is dynamically tuned.\",\n      \"evidence\": \"Co-IP, CaSR/PKC/WNK4 pharmacology, S261 and unique-region-2 mutagenesis, immunofluorescence\",\n      \"pmids\": [\"31318316\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological calcium contexts driving this in vivo not addressed\", \"Interplay with SUMO/ubiquitin codes not integrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Solidified ZO-2 as a Hippo scaffold and TEAD-localization regulator, and established cell-type-specific liver phenotypes including YAP/TAZ-dependent hepatocyte transdifferentiation.\",\n      \"evidence\": \"Co-IP with LATS1, PLA/pull-down for TEAD, nPKC pharmacology, conditional liver Tjp2 KO with cholic acid/DDC challenge and Yap/Taz genetic epistasis\",\n      \"pmids\": [\"34689705\", \"34010016\", \"33465371\", \"36151109\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of junctional vs nuclear ZO-2 to Hippo output unresolved\", \"How transporter mislocalization arises mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mapped K48-polyubiquitination acceptor sites (K759/K992) controlling ZO-2 half-life and showed PTM crosstalk with the K730 SUMO site, tying degradation control to tight-junction sealing.\",\n      \"evidence\": \"TUBE assay, ubiquitin co-IP, K730/K759/K992 mutagenesis, cycloheximide chase, TER measurement\",\n      \"pmids\": [\"36291162\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase responsible for ZO-2 ubiquitination not identified\", \"In vivo relevance of half-life control untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended ZO-2's growth-suppressive scaffolding into LATS-dependent contact inhibition and tumor suppression via p190A RhoGAP, and into ERK2 modulation downstream of ZNF582.\",\n      \"evidence\": \"Co-IP, siRNA knockdown, LATS kinase assays, in vivo tumorigenesis and proteomics/ccRCC models\",\n      \"pmids\": [\"37995182\", \"36966163\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect nature of some interactions not fully resolved\", \"Tissue-specificity of tumor-suppressive vs other roles unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided the domain-level mechanism by which ZO-2 scaffolds LATS1-YAP (SH3 binds LATS1, PDZ binds YAP) and stabilizes LATS1, and revealed ZO-2 control of junctional mechanics and tension.\",\n      \"evidence\": \"Co-IP with SH3/PDZ mutants, YAP phosphorylation and LATS1 stability assays; AFM and FRET tension probes with siRNA knockdown\",\n      \"pmids\": [\"39462647\", \"38473701\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of the LATS1-ZO-2-YAP assembly not solved\", \"How mechanical state feeds back to Hippo output incomplete\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Uncovered non-junctional roles of ZO-2 at centrioles/spindle poles in microtubule stability and ciliogenesis, plus phosphoregulation by c-Abl/JAK1 and a requirement for NTCP surface display and HBV infection.\",\n      \"evidence\": \"Co-IP with ZO-2 segments, EB1 live imaging and spindle analysis; in vitro c-Abl kinase assay with RNAi rescue and traction force microscopy; LC-MS/MS, KD/KO and HBV infection assays\",\n      \"pmids\": [\"40728639\", \"41259016\", \"41870046\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism coupling ZO-2 to spindle pole factors not structurally defined\", \"Whether NTCP/HBV role generalizes beyond hepatocytes untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the integrated PTM code (SUMO/ubiquitin/phosphorylation/14-3-3) and the choice between junctional, nuclear, and centrosomal ZO-2 pools are coordinated in vivo to dictate barrier function versus growth control remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of full-length ZO-2 in any scaffolding complex\", \"E3 ligase and full PTM regulatory network unidentified\", \"Causal link between junctional disruption and bile transporter mislocalization mechanistically incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 3, 5, 38]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [3, 5]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [11, 18]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [33, 38]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005923\", \"supporting_discovery_ids\": [0, 2, 15]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 17]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [7, 12, 22]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [11, 18]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [40]},\n      {\"term_id\": \"GO:0005929\", \"supporting_discovery_ids\": [40]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [24, 27, 33, 38]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [11, 18, 31]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 2, 15, 17]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [18, 27, 40]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [19, 34]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [26, 32, 42]}\n    ],\n    \"complexes\": [\n      \"tight junction\",\n      \"JAM-A/afadin/PDZ-GEF1/Rap2c module\",\n      \"LATS1-ZO-2-YAP Hippo scaffold\"\n    ],\n    \"partners\": [\n      \"TJP1\",\n      \"CLDN1\",\n      \"OCLN\",\n      \"F11R\",\n      \"LATS1\",\n      \"YAP1\",\n      \"SLC10A1\",\n      \"ACTN\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}